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Biotherapeutics are lifesaving drugs, but their cost is prohibitively high for 
widespread use. Multiple chromatography operations required to meet stringent regulatory 
standards, contributes up to 70% of manufacturing cost. Mixed-mode resins are emerging 
chromatographic media having multimodal chemistries promising enhanced process 
selectivity. Their potential to reduce the number of chromatography operations employed, 
is key to improving affordability of biotherapeutics. This dissertation assessed the 
capabilities of mixed-mode resins, using two recombinant therapeutic proteins with 
challenging purification needs.  
Mixed-mode ceramic hydroxyapatite (CHT) resin, was tested on microalgae, 
Chlamydomonas reinhardtii lysate, containing phosphorylated bone regenerative protein, 
osteopontin, in low purity (0.1-0.2% w/w). Complete binding of osteopontin to CHT 
through electrostatic interactions and Ca2+ coordination required 1500 mM sodium 
phosphate followed by 100 mM NaOH elution buffers to recover 86% of osteopontin. 
CHT distinguished between phosphorylated and non-phosphorylated Escherichia coli 
osteopontin, however, also co-purified impurity proteins (Rubisco) with similar 
properties.  
Versatility of mixed-mode resins was tested with osteopontin lacking 
phosphorylation, expressed intracellularly in E. coli. High-throughput screening of mixed-
mode resins, established HEA HyperCel as the capture chromatography promising 14-




HyperCel, the interaction with Capto Q resin was orthogonal resulting in 95% purity and 
44% overall recovery. 
For the potential treatment of cystic fibrosis, human thioredoxin, was expressed in 
E. coli in high titers. HEA HyperCel resin bound thioredoxin at moderate conductivity of 
5 mS and provided highest elution purity. However, unlike osteopontin, elution with NaCl 
buffer had the caveat of 45% thioredoxin recovery. Molecular modelling revealed 
existence of electrostatic and van der Waals interactions, supplementing experimental 
results. Simultaneous targeting of all interactions with 0.1 M arginine in 1 M NaCl buffer 
resulted in 100% recovery of biologically active, monomeric thioredoxin.  
This study established that mixed-mode resins fare well in capturing therapeutic 
proteins from complex lysates, irrespective of the expression titer. Their flexibility in 
binding conditions eliminate the processing cost and time associated with conditioning 
operations. However, the protein-ligand interaction is driven by the properties of the target 
protein and process development with a thorough understanding of interaction mechanism 
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INTRODUCTION AND LITERATURE REVIEW 
1.1 Introduction 
Biopharmaceuticals are biological materials including proteins, nucleic acids, cells 
and viral vectors that are of therapeutic value [1]. They can mediate several functions 
including replacement of deficient proteins, effector functions, receptor blocking, enzyme 
inhibition, stimulating biological response, etc. [2]. Their wide range of applications have 
been effective in the treatment and alleviating the symptoms of diabetes, cancer, 
inflammatory and autoimmune diseases, neurodegenerative diseases, cardiovascular 
disease, genetic diseases and much more. 
Biopharmaceuticals or biotherapeutics are a burgeoning market accounting for 
$188 billion in sales in 2017 alone and growing rapidly [3]. Currently, there are 316 
approved biopharmaceutical products in the United States and European Union [3]. The 
advent of recombinant DNA technology was the driving force behind the rise of 
biotherapeutics. It enabled large-scale commercial manufacturing of therapeutics with 
consistent quality, overcoming the variability and complexity associated with native 
source material. Additionally, it opened up the possibility of novel modifications that 
would improve the efficacy and impart additional properties to therapeutics. There are 
several categories of biopharmaceuticals, shown in Figure 1.1. Monoclonal antibodies 
(mAb) dominate the current biologics market (37%), followed by vaccines (28%) and 






Figure 1.1 Major categories of biopharmaceuticals (Reprinted from Jacoby, R., 2015 
[4]) 
 
On an average, the cost of a therapeutic ranges from $100-1000/g with a 2-5 g dose 
required per person per year, compared to $5/g of chemically synthesized drugs [5]. 
Regulatory authorities Food and Drug Association and European Medicines Agency, have 
set stringent guidelines for the quality of therapeutic products depending on the route of 
administration. Typically the final therapeutic should contain ≤ 1 µg concentration per 
dose of impurity proteins, 10 ng per dose of DNA, 10-100 EU per mg of endotoxins, 0.5% 
aggregates and 12-20 log reduction in viral loads [6-9]. The regulatory agencies also 
mandate current good manufacturing practice (cGMP) compliance for biologics 
manufacturing due to the intended human consumption. Thorough characterization of the 
product including purity, potency, stability, immunogenicity, pharmacodynamics and 
pharmacokinetics as well as the contaminant nucleic acids, viruses, pyrogens, residual host 
cell proteins, etc. need to be analyzed [10]. The manufacturing operation has to be 




mandated. Cleaning, sterilization and validation between batches of manufacturing, 
minimize batch-to-batch variations and contribute to the increased cost of goods. Recent 
trends of reducing the time for cleaning and validation by switching to disposable single-
use components, have also exacerbated the cost of manufacturing. All of these 
manufacturing requirements and the cost associated with it, reflect in the exorbitant cost 
of biologics [11]. 
The process for therapeutic manufacturing can be classified into stages of cell line 
development, upstream processing, downstream processing and formulation. Because cell 
line development and product formulation are beyond the scope of this dissertation, only 
upstream and downstream processing will be further reviewed. 
1.1.1 Upstream Processing 
Upstream processing entails the propagation and subsequent large-scale 
fermentation of biological organism to produce biopharmaceutical. A wide-range of 
organisms ranging from bacteria, fungi, plants, mammalian and human cells have been 
explored for producing biotherapeutics. The choice of expression system is dependent on 
the properties of the therapeutic, its proper folding and post-translational modification, 
immunogenicity, method of delivery, and the contaminants specific to the expression 
system. The cells are then grown in large-scale to produce the therapeutics during 
upstream processing. The quantities of therapeutic expressed or “expression titers” dictate 
the productivity of the expression system. The cost of upstream processing is directly 
associated with protein expression levels. A tenfold increase in expression titer results in 




improving cell viability and mode of fermenter operation have successfully enhanced the 
expression titers [12]. Advancements in chemically defined and serum-free media have 
reduced batch-to-batch variations of cell culture, simplified media optimization and 
reduced contamination [13]. Taken together, currently the process scale for mammalian 
cell stands at 20,000 L bioreactors operated for 2-3 weeks under fed-batch or perfusion 
conditions to accumulate 107/mL cell density [12]. Biomass accumulation and therapeutic 
protein concentration vary depending on expression system and mode of growth, but high 
density E. coli cultures accumulate biomass of 20-175 g dry weight/L expressing 5 g/L 
therapeutics while yeast cells report 130 g dry weight/L expressing 4-14 g/L of therapeutic 
[14]. Plant cell cultures can accumulate 0.02-0.2% w/w of their dry weight in recombinant 
therapeutic and mammalian cells can now regularly secrete 5 g/L of monoclonal 
antibodies [15]. As a result of the explosive improvement in expression titers and cell 
viability, upstream processing costs have been on a steady decline. 
1.1.2 Downstream Processing  
Downstream processing is defined as a sequence of unit operations employed to 
isolate the therapeutic product from the impurities. The process begins with large volumes 
of relatively low product concentration generated from upstream processing with the end 
goal of increasing product concentration and purity, conforming to the guidelines set by 
regulatory bodies. First, removal of the cells used for expressing the biotherapeutic 
(extracellular product), or extraction of the product from the cells and consequent removal 
of cell debris is entailed in primary recovery. Figure 1.2 shows a typical downstream 




bed chromatography is the workhorse of downstream processing, because of its 
unparalleled resolution [16]. In order to achieve the desired purity, three chromatography 
operations are typically employed. The first chromatography is called capture, with the 
goal to reduce the handling volume and separate major impurities. The second or 
intermediate chromatography is employed to enhance the purity followed by an optional 
polishing step to concentrate and obtain the therapeutic in the desired specification. In 
order to maximize the process selectivity, each chromatography is required to be 
orthogonal targeting different properties of the protein. Often, a complimentary 
chromatography is preferred where the end product from the previous operation is 
compatible for direct loading on the next operation. Contrary to that, an additional 
conditioning operation, such as buffer exchange, salt addition or removal would be 
necessary, which increases the number of unit operations in the downstream process. 
Minimal processing steps would be ideal for the following reasons- 1) each unit operation 
contributes to product loss 2) reduce the cost associated with each operation 3) keep the 






Figure 1.2 Strategy for downstream process development to isolate recombinant 
biotherapeutics 
 
Upstream productivity (combined cell density and titers) is critical prerequisite for 
an efficient downstream processing. With the advances in upstream processing, 
production of therapeutics has become extremely efficient. However, downstream 
processing is the bottleneck and accounts for 50-80% of the total manufacturing cost [17]. 
Chromatography is the most expensive part, accounting for up to 70% of the cost of 
therapeutics manufacturing in some cases [18]. The high cost associated with 
chromatography mainly arises from the cost of resin, long cycle times, cleaning and 
validation requirements for reuse [18]. The current processes are often inefficient resulting 
in 50% waste of product [19]. Comprehensive downstream process development 
embracing new technologies is key to minimizing the cost of manufacturing which would 
translate to affordable therapeutics. Currently, the basis for downstream process 




selection of unit operations for each product and expression system [17]. The resulting 
process is often suboptimal with inefficient resource utilization and extensive 
experimental requirements. Significant time and resource is spent on optimizing each unit 
operation that fails to conform to the scale of operation. 
Recent developments in automation and modelling, have allowed for high-
throughput experimental screening and algorithm-based methods for process 
development. Miniaturization, automation and parallelization combined led to the 
development of robotic liquid-handling instruments capable of processing up to 1536-well 
plates. Several process parameters such as chromatography conditions, binding isotherm 
and resin binding capacity can be monitored by high-throughput screening [20]. On the 
other hand, an algorithmic approach minimizes the number of experiments by mathematic 
modelling and computer simulations to predict the purification behavior. However, for 
accurate predictions, extensive database on chromatography resin properties, product and 
protein impurity information and biological thermodynamics are necessary [17]. 
Therefore, a hybrid approach combining the advantages of these developments has 
emerged as a promising candidate [21]. Combination of a hybrid-approach and thorough 
optimization, improves the process productivity resulting in lower production cost. Using 
the hybrid approach a platform could be created for downstream process development of 
therapeutic proteins with similar properties that fall under the same category. An example 
of such a template is with mAbs that constitutes 37% of all biologic drugs [4]. Since, mAbs 
have a shared fragment crystallizable (Fc) region, the downstream process often involves 




and additional orthogonal viral clearance steps. Such a cascade template, allows for 
standardization with reduced time-to-market [17]. However, recombinant therapeutic 
proteins, the other major class of therapeutics (Figure 1.1), are diverse in properties, 
application and expression system. They do not have a common motif, therefore a 
generalized downstream purification platform is not possible for recombinant proteins. 
Therefore, the downstream process design is strenuous and has to be custom developed 
without prior knowledge of the compatible chromatography. In the absence of a 
purification platform, downstream processing cost could be lowered by designing an 
efficient process based on knowledge of protein chemistry, properties of impurities and 
novel non-affinity resins, preferably reducing the number of chromatography steps. 
Process flow diagram in Figure 1.2 suggests that the optimization of capture 
chromatography would have the maximum impact on process efficiency, improving its 
selectivity could render multiple chromatography steps redundant. The technological 
advances in chromatography adsorbents offering enhanced selectivity and their 
performance as capture chromatography were explored. 
1.1.3 The Promise of Mixed-Mode Resins 
Mixed-mode resins are an emerging class of chromatography adsorbents. They 
interact with the solutes through two or more interaction mechanisms that are orthogonal, 
promising enhanced selectivity [22]. As the capabilities of traditional chromatography 
methods stagnated, mixed-mode resins have emerged as a potential alternative in 
downstream processing. They offer higher resolution, high binding capacity, better sample 




selectivity could replace the need for multiple single-mode chromatography resins, 
reducing the number of unit operations and consequently the cost of downstream 
processing [23]. Currently, mixed-mode resins have been applied as the capture and 
polishing chromatography for mAb to minimize the number of chromatography steps in 
mAb platform [24, 25]. Mixed-mode resins have not been tested extensively for direct 
capture of other classes of biotherapeutics expressed in different expression hosts.  
There are multiple possible chemistries of mixed-mode ligands, some of which are 
shown in Figure 1.3, they offer a range of interaction combinations, enabling improved 
selectivity. However, the multiple interactions make it hard to predict the protein-ligand 
interaction behavior. Thermodynamic modelling and experimental isotherms have been 
developed to predict behavior of model protein bovine serum albumin (BSA) with mixed-
mode resins [26]. Quantitative structure–property relationship models and molecular 
simulations have also been explored for other model proteins [27, 28]. These efforts have 
immensely contributed to understanding the possible interaction chemistries offered, but 
are not equipped to handle the experimental reality of complex feed material. The 
performance of mixed-mode resins in situations with complex lysates and unexplored 
therapeutic proteins is still unclear. The selectivity of these novel adsorbents could be the 





Figure 1.3 Possible chemistries of mixed-mode ligands (Reprinted from Kallberg, K. et 




This dissertation aims at addressing some of the following lacking information 
around the promise and pitfalls of mixed-mode resins- 
i. Selectivity of mixed-mode resins as a capture chromatography when applied to 
different feed streams and challenged with separating isoforms or impurities with 
similar properties 
ii. Impact of starting purity and expression titer on efficiency of the resin 
iii. Explore the possible protein-ligand interaction mechanisms and variation depending 
on the protein properties 
iv. Investigate the suitability for direct capture from complex lysates and flexibility of 
binding conditions 
v. Study protein recovery and the mechanism of action of buffer modifiers  
These parameters were evaluated by employing mixed-mode resins in the 
downstream processing of two radically different recombinant therapeutic proteins with 
challenging purification needs. 
1. A low concentration acidic protein (osteopontin) with post-translational 
modifications, expressed in Chlamydomonas reinhardtii, containing plant-like 
lipids, chloroplast protein impurities.  
2. A high concentration acidic protein (thioredoxin) with low ionic and hydrophobic 
properties, expressed in E. coli, containing possible aggregates, endotoxins and 






1.2 Literature Review 
Detailed literature review on the mixed-mode chromatography resins and proteins 
that are the focus of this dissertation are discussed next. 
1.2.1 Mixed-Mode Resins 
Yang et al., reviewed the history of mixed-mode resins, the first recognized resin 
was hydroxyapatite in 1956 by Tiselius et al. [23, 30]. Hydroxyapatite was predominately 
used in DNA separation till Burton and Harding’s work on Hydrophobic Charge Induction 
Chromatography in 1998 [31]. They discovered that hydrophobic ligands with charge 
interactions interacted with chymosin in a salt-independent, pH dependent condition and 
offered enhanced selectivity [32]. This renewed the interest in mixed-mode resins for 
therapeutic protein application. The technological advancement to manufacture designer 
ligands and control their uniform distribution on resin beads has fueled their rise [22]. 
Currently, mixed-mode resins have predominantly been applied as a pseudo-affinity 
alternative to Protein A chromatography in mAb isolation, both as capture or polishing 
step [24]. IgG1 isolation incorporating mixed-mode resins MEP and CHT after Protein A 
chromatography, showed increased reduction in aggregates and improved the protein 
recovery [33]. Successful isolation of recombinant human vascular endothelial growth 
factors from E. coli inclusion bodies using mixed-mode resin, Capto MMC was 
accomplished on pilot and manufacturing scales [22]. Other than proteins, peptides and 




The multiple protein-ligand interactions can be simultaneous or separate. When 
the interactions are separate, or individual retention mode, each mode of interaction can 
be brought on and controlled by manipulating the process conditions. As a result, a “U-
shaped” elution profile ensues, due to the shift between interaction chemistries. For 
example, BSA interacts electrostatically with benzylamine ligand on Cell-SSP-BA mixed 
mode resin at pH 4.2. As the NaCl concentration increases, the protein desorbs from the 
ligand by reversal of electrostatic interaction due to electrostatic shielding. When the NaCl 
concentration increases beyond 0.5 M, hydrophobic interactions cause BSA to interact 
with the ligand again [34]. The advantage of individual retention mode is that it can be 
easily understood and implemented [23]. When the multiple interactions are simultaneous, 
combined retention mode occurs. With such interactions, it becomes hard to predict the 
retention and elution behavior of proteins. Predictive approaches with adsorption 
isotherms, molecular modeling and quantitative structure–property relationship have been 
applied to forecast the interactions for process development.  
The complex nature of these interactions make process development with mixed-
mode resins notorious for low protein recovery. Eluents such as NaCl, pH changes or 
addition of competitor are often insufficient. Extraordinary efforts are necessary to 
counteract all the interactions and release the bound proteins. Several additives to the 
elution buffers have been studied for this purpose, called elution buffer modifiers, which 
include arginine, guanidine, sodium caprylate, various polyols, urea, glycine, ethanol, etc. 
[35, 36]. The impact of these modifiers on mixed-mode resins have been explored, 




impact the hydrophobic interaction and promote ionic interactions [37]. Chaotropes such 
as urea and guanidine affect hydrogen bonds and hydrophobic interactions, exposing the 
secondary structure, especially with large proteins. Arginine, typically used in protein 
formulation to maintain structural conformational stability has been extensively used as 
an elution modifier. Due to the guanidinium group in its structure, it elicits the same 
properties, combined with aggregate solubilization and possible structural changes [35, 
36]. Kalease et al., in the study with recombinant human vascular endothelial growth 
factors, they employed 0.8-1 M arginine in combination with NaCl to elute the protein 
from Capto MMC, inconclusively questioning whether arginine acted on the hydrophobic 
or hydrogen bonding [22]. In another study, the same Capto MMC mixed-mode resin 
displayed complete desorption of ubiquitin and papain with 0.1 M arginine, while 
lysozyme and avidin required arginine in combination with high NaCl concentrations for 
elution [36]. Therefore, the protein interactions with mixed-mode resins are not 
straightforward and require further studies to be fully understood. 
1.2.1.1 Ceramic Hydroxyapatite Resin 
Ceramic hydroxyapatite (CHT) was the earliest mixed-mode resins, used for 
therapeutic protein isolation in 1950s [38]. Hydroxyapatite is a naturally occurring mineral 
crystal composed of calcium, phosphate and oxygen with a chemical formulae of 
Ca10(PO4)6(OH)2. It is widely present in biological materials as the structural component 
of teeth enamel and bones. When sintered at high temperatures, porous beads of ceramic 




CHT has a uniform composition throughout the matrix, in contrast to typical 
chromatography resins that have functional ligands immobilized on a bead with the help 
of a spacer arm. As a result, CHT has high pressure tolerance and better flow properties 
[39]. The possible interactions with CHT resin is shown in Figure 1.4. Electrostatic 
interactions with the positively charged calcium sites and negatively charged phosphate 
sites are possible, enabling separations for both acidic and basic proteins. Additionally, 
coordinate bonds formed by metal affinity interactions with the calcium sites are also 
possible. The coordinate bonds at calcium sites are much stronger than electrostatic 
interactions and NaCl is insufficient to elute them even at concentrations up to 4 M [39, 
40]. Although the interaction mechanisms can be broadly classified, the elution of target 
proteins is more complex and cannot be considered as simple reversal of the binding 
mechanism. Extensive investigation into the available elution salts and modifiers by 






Figure 1.4 Possible interaction mechanisms of CHT resin (Reprinted from Hilbrig, F. et 
al., 2012 [39]) 
 
Monoclonal antibodies, viral vectors, nucleic acids and several proteins have been 
purified with CHT. Notably, aggregate and fragment separation from mAb is a lucrative 
property of CHT [43, 44]. The specificity of CHT towards phosphopeptides and 
phospholipids are of special interest to this study. Fractionation of casein peptides based 
on the number of phosphorylations has been achieved using a phosphate elution gradient 
on hydroxyapatite chromatography [45]. The same research group also investigated 
phospholipids separation from buttermilk and egg yolks. Although the resin successfully 
separated triacylglycerols from phospholipids, they report that other non-phosphorylated 
lipids were also bound to the resin by hydrogen bonds. The elution of these phospholipids 
was also difficult and required extensive testing due to the strong interaction by pseudo-
affinity [46]. Finally, phosphoprotein separation using CHT is much less prevalent, due to 




tertiary structure [47]. Phosvitin, a phosphorylated egg protein reportedly required 
exceptionally high concentrations of phosphate in the elution buffers [48]. Therefore, CHT 
is a powerful and complex chromatography resin, but the success of its application is 
dependent on the biochemical characteristics of the material to be separated. 
1.2.1.2 HyperCel Resins 
The family of HyperCel resins are commercial mixed-mode resins by Pall Life 
sciences. They consist of MEP, HEA and PPA HyperCel resins, with ligands on a cellulose 
bead. MEP (4-Mercapto-Ethyl-Pyridine) is a hydrophobic charge induction 
chromatography resin that allows for hydrophobic interactions at low salt and elution is 
achieved by charge repulsion. MEP is prominently used as an alternative to Protein A 
chromatography for mAb capture [49]. HEA and PPA HyperCel resin have aliphatic and 
aromatic hydrocarbons respectively, with a charged ligand. The hydrocarbons promote 
protein binding in low to moderate conductivity, eliminating the need for conditioning 
[35]. Human IgG isolation process has incorporated HEA HyperCel as the capture 
chromatography resin in a 3 step orthogonal purification train [50]. Applying design of 
experiments (DoE) approach, HEA HyperCel was employed on E. coli lysate to obtain 
89% recovery of granulocyte colony stimulating factor at 99.16% purity [20]. Other 
recombinant proteins including zinc metalloenzyme, lactoferrin have also successfully 
incorporated HyperCel resins in their purification train [51, 52]. 
HyperCel resins offer multiple-mode of interaction with the proteins such as 
electrostatic, hydrophobic and hydrogen bonding. The types of interactions were shown 




different pI [35]. Acidic proteins such as BSA, ovalbumin and catalase were efficiently 
adsorbed by HEA and PPA HyperCel resins at pH > pI of proteins at low conductivity, 
but increasing the conductivity was insufficient for their elution [35]. This is due to 
multiple interaction mechanisms that act simultaneously and need to be reversed for 
efficient protein elution. Consequently, extensive screening of binding and elution 
conditions is a crucial part of process development using mixed-mode resins. High-
throughput screening on filter plates is a common approach for selecting the appropriate 
process conditions [24, 53, 54]. Mathematical-model based predictions and molecular 
simulations are also gaining prominence to relieve the experimental load [26, 27]. 
Several elution buffers with modifier salts have been carefully tested for efficient 
protein recovery and to understand the protein-ligand interaction of HyperCel resins. Most 
commonly, a variety of salts, urea, arginine, guanidine, glycine and glycerol have been 
tested. In the study of lysozyme retention on HyperCel resins, the nature of anion and 
cation of the salt used strongly impacted the retention. While sodium chloride and sulfate 
promotes retention time by improving hydrophobic interactions, sodium acetate was 
shown to decrease the lysozyme binding [35]. Organic solvents, ethanol, glycerol and 
ethylene glycol, have been applied to counteract hydrophobic interactions of bovine 
gamma-globulin with MEP HyperCel [55]. Ethanol in the presence of 1.5 M NaCl was 
effective in eluting human growth factor, when ethanol by itself was ineffective, 
highlighting the necessity to break multiple interactions simultaneously [22]. Depending 
on the protein, arginine has the ability to break electrostatic, hydrophobic and hydrogen 




arginine was employed to break hydrophobic interactions efficiently [55]. A 80-90% 
recovery of human granulocyte colony stimulating factor from HEA HyperCel resin was 
possible with only NaCl elution [20]. Therefore, there are several possible protein-specific 
interactions with HyperCel resins that need to be explored during process development. 
1.2.2 Therapeutic Proteins Structure and Biological Function 
1.2.2.1 Osteopontin 
Osteopontin (OPN), also called bone sialoprotein (BSP-1), is mammalian protein 
expressed by a wide range of cells (bone, smooth muscle cells, vascular tissue, brain cells, 
epithelial cells of mammary salivary glands, macrophages and lymphocytes, etc.) and 
secreted in bodily fluids (milk, blood, urine, etc.). Nascent OPN is made up of ~300 amino 
acids, with acidic amino acids (aspartic acid and glutamic acid) making up 25% and serine 
contributing to 15% of the primary sequence. The resultant protein is acidic with a 
theoretical pI of 4.5. The primary amino acid sequence varies between mammals, however 
functional amino acid sequences are predominantly conserved [56]. The functionality of 
OPN arises from its distinctive amino acid sequences (Figure 1.5), RGD (arginine-
glycine-aspartic acid) sequence, polyaspartate domain, thrombin cleavage site, multiple 







Figure 1.5 Amino acid sequence of OPN showing functional sites (Reprinted from 
Kazanecki, C.C. et al., 2007  [58]) 
 
The primary function of OPN is bone resorption and regeneration during wound 
healing. The RGD sequence is an integrin binding site that is centrally located (128-130 
aa) close to the thrombin cleavage sequence [59, 60]. OPN is secreted by macrophages as 
a response to injury or inflammation, accumulating at the injury site where it acts as an 
opsonin. The RGD sequence of OPN attracts the phagocytic osteoclasts to the injury site, 
promoting debris and bacterial clearance in a process of bone resorption [61]. Osteoclasts 
in turn secrete OPN, enriching it in the cement layer, the newly exposed surface of the old 
bone which is primed for regeneration. Here, OPN bridges new osteoblast cells with the 
hydroxyapatite in the bone matrix through its polyaspartic sequence (70-78 aa), mediating 
bone regeneration [61]. Calcium binding sites and phosphorylated serines prevent 
spontaneous precipitation of calcium and impede nucleation of hydroxyapatite or calcium 
oxalate crystals [56]. The charge distribution in the polyaspartic acid sequence is attributed 




binding regions are involved in immediate response to inflammation and wound healing 
[63]. OPN is also an immunomodulator of Th1 mediated response to induce antibody 
production and B-cell proliferation [64].  
The secondary structure is predicted based on circular dichroism studies, consists 
of 8 α-helices in 2 clusters, concentrated towards the C-terminal region [56, 65]. The RGD 
sequence and thrombin cleavage site are flanked between short β sheets, similar to the 
structure of fibronectin [65]. The tertiary structure is not defined with reports that 
characterize OPN with an open, flexible structure by nuclear magnetic resonance and 
sparse hydrophobic regions [58, 66]. This flexibility in structure allows interaction with 
multiple proteins such as collagen, fibronectin, osteocalcin, etc. [59]. 
Several potential post-translational modifications (PTM) sites–28 phosphorylation 
and 6 glycosylation sites, are present [58, 67] and in some cases sulfation and crosslinking 
are also possible [68]. Sites for these modifications, vary depending on the source of OPN, 
bovine milk, human milk and rat bone OPN have 32, 28 and 11 phosphorylations 
respectively [64]. Glycosylation patterns also vary, bovine and human milk have reported 
3 (Thr 115, Thr 124, and Thr 129) and 5 N-linked glycosylations (Thr134, Thr138, 
Thr143, Thr147 and Thr152) while rat bone OPN has one N-linked and up to six O-linked 
glycosylated residues [67, 69]. The post-translational modifications in OPN vary with the 
expressing tissue and as necessitated by its multitude of cellular functionality [69, 70].  
Post-translational modifications are key to the immune, mineralization and bone 
remodeling functionalities of OPN. In wound healing, phosphorylation promotes 




immunity was dependent on OPN phosphorylation [72]. The ability of OPN to inhibit 
hydroxyapatite crystal seeding and growth was lost upon dephosphorylation in de novo 
studies [73]. Similarly, preventing calcification of smooth muscle cells was proportional 
to the dosage and number of phosphorylation in OPN and was lost upon 
dephosphorylation [74]. Glycosylation affects protein conformation and stability, it 
reduces phosphorylation and thereby indirectly impacting cell adhesion [75]. N-linked 
glycosylated rat kidney OPN was not phosphorylated, and retains cell adhesion properties, 
signifying that cells modify OPN to their intended function [70]. O-glycosylation regulates 
protein phosphorylation and conformational stability of the protein [75]. Fully 
glycosylated OPN displayed higher cell adhesion properties [75]. OPN is extensively 
susceptible to fragmentation and proteolytic degradation by serine proteases, thrombin and 
multiple metallo-proteases (MMP). The variation in PTMs and fragmentations gives rise 
to isoforms of OPN with widely different reported molecular weight ranging from 70 to 
44 kDa full length OPN and 40 to 20 kDa and smaller peptide fragments, and pI varying 
from 3 to 4.7 [59, 70, 76]. The fragments of OPN are functionally significant. The amino 
terminal of thrombin and MMP cleaved OPN contains RGD motif and exhibits integrin 
binding and cell adhesion properties independent of the full protein [77]. Notably, the 
fragment displayed 2-fold enhanced cell migration than the full protein [78]. The C-
terminal fragment of thrombin and MMP cleavage, suppress the migration of monocyte-
derived cells [79]. However, irrespective of the terminal, phosphorylated fragments of 




heterologous isoforms, modifications and fragments of OPN, each with distinct biological 
and structural properties adds to the complexity of downstream process development. 
Therapeutic Properties of Osteopontin 
Osteopontin can be administrated as a therapeutic for the following diseases- 
Bone health and wound healing- Although OPN is not required for the initial bone 
development and osteogenesis, it is crucial in maintaining the bone health during 
remodeling [80]. During wound healing, such as in the case of fractures, osteopontin is 
responsible for two stages of wound healing. First, it is secreted by macrophages in 
response to an injury or necrosis site, where it promotes further macrophage secretion. 
Acting as an opsonin, it is crucial in wound debriment, clearance of bacteria and 
particulates [61]. Second, OPN is responsible for bone remodeling, a continuous bone 
regeneration process. It begins with osteoclasts that resorb old bone to expose an interface 
for new cells to attach. Osteoblasts secrete OPN, to bind to the old bone interface as a 
“cement line” and promotes adhesion of the new bone cells [61]. Mice with reduced OPN 
levels developed osteopetrosis, attributed to the inability of osteoclasts to adhere and 
resorb old bone [81]. 
Neuroprotection after stroke- Ischemic damage is the loss of blood supply to 
tissues after a stroke. Due to the reported over expression of OPN in the brain after 
ischemia, indicative of macrophage mediated cell repair [82], the therapeutic effect was 
investigated. In in vivo mice studies, effects of cerebral focal ischemia was induced 
surgically for 60 mins with oxygen and glucose starvation of neuron for 120 mins. In a 




death 2-fold [83]. In vivo studies showed 2-fold reduction in the size of infracts with OPN 
treatment. OPN provided the same neuro protective effect when administered 24-h before 
or after the ischemia induction. Similarly, OPN has been proved effective in improving 
cell viability after kidney ischemia. Several studies note the expression of OPN in 
damaged cells, that affect morphological regeneration [84, 85]. 
Inflammatory diseases- Osteopontin has been upregulated in several inflammatory 
diseases, as a result it can be a biomarker in disease prognosis. Multiple sclerosis (MS) 
affects the brain and nervous system by demyelinating the neurons, primarily attributed to 
T-cells misregulation. In animal models of MS, autoimmune encephalomyelitis (EAE), 
expresses increased OPN levels that enable survival of T-cells, that in turn exasperates the 
disease [86]. In rheumatoid arthritis, a synovial inflammatory disease leading to cartilage 
and bone destruction, IL-1 and TNF α are the major causative agents. OPN and thrombin 
cleaved OPN enable the secretion of these pro-inflammatory molecules through T-cell 
proliferation [87]. A similar role was observed in Crohn’s disease and allergic asthma. 
Therefore OPN is a therapeutic drug target in the treatment of these T-cell mediated 
inflammatory diseases [87].  
In cardiovascular disease, an inflammatory disease of the blood vessels, OPN 
exhibits dual roles. In the initial stages, OPN induces atherosclerosis lesions by 
macrophage induced inflammation [88]. As the disease progresses, vascular calcification 
of the tissue leads to organ failure. In mice studies, OPN deficient mice have accelerated 
calcification by calcium phosphate deposits. OPN as an injection or adsorption into 




Phosphorylation and RGD domain played a key role in inhibition of the calcification [74, 
89]. The mechanism of OPN prevention of calcification is three-fold. 1) OPN binds to 
crystal hydroxyapatite (Ca-Phosphate salt) and consequently prevents further deposition 
of minerals and avoids crystal growth, 2) Promotes macrophage cytokine secretion to 
dissolve mineral deposits and 3) opsonin activity with specificity towards mineral and cell 
adhesion [90]. This similar mechanism is also employed in preventing calcifications of 
the kidney as well. 
Cancer cells also over express OPN, and is often considered a biomarker of tumor 
metastasis. In a recent review [91], all the applications of OPN as a cancer target to 
suppress tumors was summarized. 
OPN Isolation Processes in the Literature 
The various processes reported in the literature for isolation of osteopontin are 
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exchange 
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Urine [95] 1) DEAE sepharose 
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isoelectric 
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2) Ammonium sulfate 
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exchange 
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exchange 
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1) pH 3.6-6.5 4-10mS 
Isoelectric 
precipitation 
2) Anion exchange 
chromatography 
using Q-sepharose 
NM NM 100 




All the reported processes employ multiple often repetitive chromatography that 
reduce the process efficiency. The process recoveries are rarely mentioned or are below 
50% at best. The new interaction chemistries and selectivity that mixed-mode resins offer 
could be of immense benefit to isolation of osteopontin. 
1.2.2.2 Thioredoxin 
Thioredoxin (Trx) is a redox protein, present in all levels of organisms ranging 
from prokaryotes to higher mammals. The thiol active site (C32-C35) is highly conserved 
and is responsible for preserving the intra-cellular environment in a reduced state. The 
mechanism is a reversible redox reaction, Trx is involved in an electron transfer from 
NADPH in the presence of thioredoxin reductase (TrxR). The active site is then oxidized 
by donating hydrogens to keep the other proteins reduced. This redox functionality is 
central for several cellular functions such DNA synthesis, oxidative-stress relief for 
regulating apoptosis to immunomodulation. Trx is a hydrogen donor to ribonucleotide 
reductase, facilitating DNA synthesis [100]. It prevents oxidative stress through electron 
donation to peroxiredoxins, which mediate reduction of H2O2. Trx also de-nitrosylates S-
nitrosoglutathione to release nitric oxide for redox signaling in neutrophils [101]. In 
mammalian cells, Trx binds to apoptosis signal-regulating kinase 1 and directly inhibits 
apoptosis to relieve cellular oxidative stress [102]. Trx is an integral structural component 






Trx is characterized by a 4 α-helices, 5 β-sheet motif and is found in several forms, 
differing in amino acid composition. Amongst bacteria such as E. coli, Helicobacter 
pylori, Rhodobacter capsulatus, Trx-1 with one active site is more abundant than the 
second isoform, Trx-2 that has 32 additional N-terminal amino acids and three dithiol 
active sites [104]. The two forms have identical functionalities, but the expression of Trx-
2 is induced by environmental stress [105]. In higher plants and algae, 3 isoforms of Trx: 
m and f are expressed in the chloroplast and h in the cystol. Each of the isoforms have 
demonstrated enzyme binding, Trx-f has 550-fold higher affinity to fructose-1,6-
bisphosphatase than Trx-m which binds better to malate dehydrogenase [106]. Hence, it 
can be construed that the evolutionary difference in the amino acid sequence of isoforms 
is tailored to the target functionality.  
Human thioredoxin (hTrx) is found in two forms Trx-1, expressed in the nuclear 
and cytoplasmic region, and Trx-2 expressed in the mitochondria. The main difference 
between the two forms is in the structure and function. Trx-1 is a 11.7 kDa protein with 5 
cysteines (C32, C35, C62, C69 and C73). C73 is close to the active site and is prone to 
oxidation, thereby leading to homodimers and loss of redox activity of proteins. Trx-2 is 
an 18 kDa protein with a 60 additional amino acids, once cleaved results in 12.2 kDa Trx-
2. The main difference is the lack of 3 structural cysteines (C62, C69 and C73), leading to 
higher stability towards some oxidants [107]. Both thioredoxins have displayed redox 
activities, Trx-2 activity is focused towards mitochondrial reduced state, regulating 
reactive oxygen species (ROS) and mitochondrial apoptosis signaling pathway [108]. 




immediately following implantation[109]. Trx-2 knockout displayed lethality in mid-
embryonic stage, when oxidative phosphorylation (ROS generation) began[110]. hTrx is 
typically found in concentrations of 28.5 ± 12.6 ng/ml in healthy human plasma [111]. 
This study focuses on the properties and structure of Trx-1, a short 105 amino acid, 
acidic protein with a pI of 4.82. The active site C32-C35 is present at the end of α2 helix and 
protrudes from the structure enhancing accessibility [112]. More than 75% of its amino 
acids are involved in the 4 α-helices, 5 β-sheet secondary structure, resulting in a highly 
ordered and stable structure [113]. This contributes to enhanced stability at high 
temperatures (Tm = 85°C ,pH 7.0) and at pH 2-11.5 [114]. Although, it is not prone to 
proteolysis due to its conformational rigidity [115], it is cleaved by cyanogen bromide and 
trypsin at 32 and 73 amino acids, respectively producing fragments with lowered activity 
[116]. The net charge of the protein is low and the hydrophobic residues are focused 
towards the C-terminal [113]. hTrx is present in a 90-100% reduced state in the cells with 
a redox potential of -230 mV [112]. Post-translational modifications are limited to 
reversible nitrosylation/denitrosylation and glutationylation of C73 under oxidative 
conditions [117, 118].  
Therapeutic Potential of Thioredoxin 
Diseases attributed to oxidative stress, stand to benefit immensely from the 
reversible redox functionality of thioredoxin. Numerous in vivo and in vitro studies in 
animal models have identified and demonstrated the effectiveness and importance of 
thioredoxin in cardiovascular, neurodegenerative and inflammatory diseases. Extensive 




Oxidation of proteins has been attributed to aging of tissues, Trx-1 has improved 
the lifespan in mice by alieving oxidative stress [121]. Cardiovascular diseases (CVD), a 
leading cause of mortality, are characterized by asymptomatic atherosclerosis, a condition 
that causes plaques and inflammation of heart tissues. Trx-1 suppresses inflammatory 
cytokines and down regulates ion channels, combating atherosclerosis [119]. Delivery of 
Trx-1 through gene therapy using an adeno virus vector has improved myocardial 
performance in rats by inhibiting proapoptic pathways [122]. 
Other inflammatory diseases such as rheumatoid arthritis, are also results of 
oxidative stress. Patients suffer from severe inflammation of synovial fluids due to 
macrophage and T-cell and cytokine influx. They secrete proteolytic enzymes resulting in 
cartilage and bone destruction [123]. Trx-1, inhibits protease expression by activation of 
the Ca2+ - Na+ ion channels [124]. Additionally, the neutrophils and macrophages release 
reactive oxygen species (ROS) intensifying the tissue damage through hydrogen peroxide 
and nitric oxide levels. Trx levels in the plasma of rheumatoid arthritis patients was 2 
times higher than control group, in defense to the oxidative stress, reinforcing the vitality 
of Trx [125, 126].  
Age-related neurodegenerative diseases such as Alzheimer's and Parkinson’s 
diseases are attributed to oxidative stress that causes necrosis of neurons and protein 
misfolding [127]. Aggregates of amyloid-β-peptide make up senile plaques causing 
oxidative stress on the brain tissue. Redox proteins like Trx-1 provide the first line of 




protected neuron cells from amyloid-β-peptide toxicity [128], indicating a direct role of 
Trx-1 in preventing senile plaques.  
Cystic fibrosis is a fatal genetic condition afflicted by mutation in the chloride 
receptor channel of mucosal membranes. Overcompensation in liquid adsorption, leads to 
concentration of mucosal proteins in the epithelial surface of the pancreases, intestines and 
lungs. Cellular secretions form a gel-like network with mucosal proteins, DNA and dead 
cells. The increased viscoelasticity of the bodily secretions, impair clearance, harboring 
infections that lead to mortality [129]. Similar to other inflammatory diseases, there exists 
an oxidative stress on pulmonary cells because of neutrophils secreting cytokines and ROS 
species. In patients, unmodulated amounts of neutrophil elastase, a serine protease is 
secreted, which degrades elastin, extracellular matrix proteins and up-regulates 
inflammatory cytokines, worsening cystic fibrosis symptoms. [130]. Trx mediates these 
symptoms by addressing multiple facets of the disease. Both E. coli and hTrx showed 
inhibition of elastase activity by directly disrupting the four disulfide bonds crucial for the 
elastase tertiary structure and activity [131]. Maximum of 60% elastase inhibition was 
achieved with 10 µM Trx, while chemical redox reagents such as dithiothreitol (DTT) 
required 8-times the concentration for the same inhibition [131]. Trx also increases the 
solubility of mucin glycoproteins and release liquid from sputum at 30 µM Trx [129]. The 






Thioredoxin Isolation Processes 
Thioredoxin is widely used as a solubility tag to avoid recombinant proteins 
accumulating in inclusion bodies. It is used in conjecture with an affinity tag such as 6x-
His or glutathione S-transferase (GST), to purify the protein. Currently, there is no known 
affinity chromatography to isolate thioredoxin using its inherent properties. 
The following processes have been reported which purify human thioredoxin from 
E. coli. They consist of multiple unit operations with repetitive steps that decrease the 
productivity/efficiency. The earliest report of human thioredoxin purified from E. coli is 
from Wollman et al. [132]. The biomass was homogenized at 125 MPa for 2 passes in 100 
mM Tris/HCl, (pH 8.0), 5 mM benzamidine HC1, 1.0 mM EDTA, 0.25 mM DDT, and 
1.0 mM sodium azide buffer. After cell debris removal by centrifugation, the conductivity 
was decreased by diluting the lysate 3-fold in 50 mM Tris/HCl pH 7.7. Then the lysate 
was loaded on DEAE-sepharose column and bound proteins eluted with a 0-500 mM NaCl 
gradient. Thioredoxin was present in the 200 mM NaCl elution, which was then dialyzed 
into 25 mM piperazine HCl (pH 5.7) buffer. A second DEAE sepharose anion exchange 
chromatography was employed with a 0 to 250 mM NaCl elution gradient. Thioredoxin 
eluted in the 125-150 mM NaCl, then it was captured and concentrated. The third 
chromatography step of size exclusion by Ultrogel AcA54 was performed in 100 mM 
Tris/HCl, 2 mM sodium azide. This process is reported to have a 40% protein recovery 
and high purity as observed by a SDS-PAGE. Stein et al., 1995,[133] elaborates on the 
process for isolating C. reinhardtii thioredoxin expressed in E. coli cells. The proteins 




MPa for 3 passes. After removal of cell debris, the lysate was heated to 70°C for 10 mins 
to denature and remove the precipitated proteins. A second pretreatment of fractional 
salting-out was applied, the thioredoxin precipitating between 40-90% ammonium sulfate 
concentrations was collected. The precipitate suspended in lysis buffer was separated by 
gravity-flow size exclusion chromatography with Sephadex G50 resin. The fractions with 
thioredoxin activity were further dialyzed to remove NaCl and subjected to anion 
exchange chromatography on DEAE sephacel column. The bound proteins were eluted 
with a 0-0.4 M NaCl linear gradient to obtain purified thioredoxin. The percent recovery 
and purity of thioredoxin from the process was not mentioned, an SDS-PAGE image 
showed no host cell protein impurities. Multiple publications by the same research group 
describe expressing and purifying thioredoxin in different systems using this process [134, 
135]. The most recent process reported is by Harris et al., 2012 [136]. The cells were 
disrupted in 10 mM Tris, 5 mM DTT, pH 7.4 buffer. Lysate was pretreated with 
ammonium sulfate precipitation and hydrophobic interaction chromatography column was 
used to capture the proteins at 2 M ammonium sulfate concentration. Thioredoxin eluted 
from hydrophobic interaction chromatography was then desalted. Intermediate anion 
exchange chromatography with Source Q resin was employed. A linear 500 mM NaCl 
gradient was used to elute thioredoxin. Further, size exclusion chromatography was 
performed to obtain hTrx at a high purity with <0.01% HCPs and 50% protein recovery. 
In summary, the processes in place for isolating thioredoxin involve at least 1 
pretreatment unit operation, followed by 3 chromatography steps. Often, these 




orthogonal chromatography steps, there are conditioning unit operations required in 
between. The maximum recovery achieved is only 50% of the initial thioredoxin. The 
current processes, are not scalable to efficiently produce the required kilogram quantities 
of hTrx required for cystic fibrosis treatment, therefore alternative processes need to be 
explored. 
1.3 Objectives and Dissertation Organization 
The objective of this study was to understand and evaluate the application of 
mixed-mode resins as it pertains to recombinant proteins with challenging downstream 
processing requirements. The impact of several factors including expression level, starting 
purity, expression system, post-translational modification were explored. This dissertation 
is organized as follows- 
Chapter I provides a general introduction of the biotherapeutics market and the 
necessity to explore technological advancements in downstream processing of 
recombinant proteins. The prospects of mixed-mode resins with the current knowledge of 
their applicability and persistent questions are presented. This chapter further introduces 
the two case studies employed to understand the versatility of mixed-mode resins. 
Literature review and insights into the two recombinant proteins, their therapeutic 
applications and respective bioprocessing challenges are provided.  
Chapters II, III and IV contain individual studies of mixed-mode resins and are 
organized similar to a scientific publication. Each chapter further provides an introduction 




study are presented, followed by discussion of the findings and a chapter-specific 
conclusion. 
Chapter II entitled “Isolation of phosphorylated osteopontin from transgenic 
Chlamydomonas reinhardtii using ceramic hydroxyapatite resin” is a study on the 
application of mixed-mode resin ceramic hydroxyapatite, to separate phosphorylated 
proteins. The specific objectives of this study were to - 
i. Evaluate the selectivity of CHT resin to capture phosphorylated proteins and explore 
its multiple interaction mechanisms to improve selectivity 
ii. Study the ability of mixed-mode resins to capture recombinant proteins expressed in 
very low starting purity, distinguish isoforms and separate them from host cell proteins 
that have similar properties  
iii. Recover at least 30% osteopontin by orthogonal batch chromatography at > 90% purity 
by employing mixed-mode resin 
Chapter III, “Exploring the separation power of mixed‐modal resins for 
purification of recombinant osteopontin from clarified Escherichia coli lysates”, discusses 
osteopontin isolation in the absence of protein phosphorylation. Several mixed-mode 
resins were tested and compared to single mode resins for protein purification and 
recovery. The specific objectives were to- 
i. Evaluate isolation of osteopontin and the binding conditions for several mixed-
mode by high-throughput screening and batch chromatography studies 





Chapter IV “High-throughput screening of mixed-mode resins and investigation 
of interaction mechanism with human thioredoxin”, explores a hybrid approach to process 
development combining high-throughput screening and molecular modelling to optimize 
protein separation from HEA HyperCel resin. The specific objectives were to- 
i. Evaluate the direct capture and flexibility in loading conditions offered by mixed-
mode resins compared to single-mode resins 
ii. Understand the underlying protein-ligand interaction mechanism and the mode of 
action of elution buffer components 
iii. Obtain active hTrx at > 95% purity and > 50% recovery using mixed-mode resins 
Finally, Chapter V summarizes the major findings and contributions of this 






ISOLATION OF PHOSPHORYLATED OSTEOPONTIN FROM TRANSGENIC 
Chlamydomonas reinhardtii USING CERAMIC HYDROXYAPATITE RESIN* 
2.1 Introduction 
The workhorse of complex protein production for nearly 56% of recombinant 
proteins is the mammalian Chinese hamster ovary (CHO) cell line [137]. The ability of 
mammalian cells to properly fold and perform post-translational modifications (PTMs) of 
proteins, out-weighs the high cultivation costs and potential viral contamination issues. 
Escherichia coli is also extensively employed to produce recombinant proteins and does 
so at a fraction of the CHO cost but the resultant proteins often lack proper folding, PTMs 
and are prone to endotoxin contamination [138]. To overcome the disadvantages of 
mammalian and bacterial expression, the unicellular microalga Chlamydomonas 
reinhardtii has been explored as an alternative protein production platform. Specifically, 
the chloroplast of C. reinhardtii has been utilized for the production of difficult-to-express 







*Part of this chapter is reprinted from Ravi A, Guo S, Rasala B, Tran M, Mayfield S, 
Nikolov ZL. Separation Options for Phosphorylated Osteopontin from Transgenic 
Microalgae Chlamydomonas reinhardtii. International Journal of Molecular Sciences. 




One such mammalian protein is osteopontin (OPN), also called bone sialoprotein-
1 (BSP1), which is present in milk, bodily fluids and is responsible for bone development 
and regeneration. Other crucial functions of OPN include prevention of renal 
calcifications, protecting cells from apoptosis [144] and cytokine activity that differentially 
regulates inflammatory and immune response to allergic reactions [145]. The native 
mammalian form of OPN is an acidic, glycosylated sialoprotein, rich in aspartic acid, 
glutamic acid and serine residues [56]. Nascent bovine OPN is a ~34 kDa (~300 amino 
acid) protein, with an isoelectric point (pI) of 4.3, an arginine-glycine-aspartic acid (RGD) 
motif, a thrombin cleavage site, a polyaspartate domain and multiple calcium binding 
sites. In addition, twenty-eight potential phosphorylation sites and 3 glycosylation sites 
have been identified in the structure of OPN [58, 67]. OPN’s phosphorylation apparently 
provides a stabilizing effect on the bond between calcium and hydroxyapatite in bones 
[73], regulates the interaction of OPN with integrins during signaling in CD44 mediated 
immune responses [72] and is vital for inhibiting vascular calcification in smooth muscle 
cells [74]. Therefore, to take advantage of the diverse beneficial activities of OPN, a 
potential recombinant protein production system should also be able to deliver optimal in 
vivo OPN phosphorylation. 
Despite the immense potential of OPN in the healthcare industry, reports dealing 
with recovery, purification and commercial applications have been relatively few. 
Attempts at purifying OPN from tissues and bones have been confined to affinity-tag 
chromatography [98, 99, 146, 147], which only allows the production of limited amounts 




Most of the methods employed to purify larger quantities of OPN, relied on generic 
protein properties such as hydrophobicity and ionic charge. Early reports with human milk 
employ weak anion exchange chromatography followed by several low capacity 
processing steps that resulted in low OPN yields due to losses from the multiple 
purification steps [92, 94]. Currently, the primary source of OPN is bovine milk whey, 
which is processed by two consecutive anion exchange chromatography steps or anion 
exchange chromatography followed by two consecutive hydrophobic interaction 
chromatography steps [57, 93]. Understandably, anion exchange adsorption is the default 
choice for capture and concentration of acidic OPN. It appears that consideration of other 
resin chemistries to increase process selectivity and yield warrants further investigation. 
The question to ask is whether the polyaspartate cluster (88–93 AA) and multiple 
phosphorylation sites in OPN can be exploited to achieve a more specific interaction with 
chromatographic adsorbents carrying transition metals and Ca2+ ions. 
Therefore, the specific objectives of this study were (1) to assess the feasibility of 
chloroplast of the microalgae C. reinhardtii to produce phosphorylated OPN and (2) to 
evaluate OPN recovery and adsorption chromatography options that could take advantage 
of phosphorylation and/or polyaspartate sequences in the OPN structure. To evaluate the 
performance of algal-produced OPN, E. coli transformed with same OPN gene construct 





2.2 Materials and Methods 
2.2.1 Cultivation of Recombinant Chlamydomonas reinhardtii Strain Expressing 
Bovine OPN  
The chloroplast genome of C. reinhardtii strain cc1670 was modified to express 
bovine OPN by California Center of Algae Biotechnology, UCSD [148]. The psbA gene 
was replaced with cDNA for bovine OPN (GenBank accession number NP_776612.1) by 
homologous recombination. The modified strain was rescued by re-insertion of the psbA 
gene at a different location in the genome. A 1×-FLAG epitope tag (DYKDDDDKS) was 
inserted at the N-terminal of OPN sequence for identification and quantification, with an 
enterokinase cleavage site to facilitate removal after OPN purification. 
Recombinant algal cells were grown on 15% Tris-Acetate-Phosphate (TAP) agar 
plates at room temperature. The colonies were transferred into TAP media containing 0.1% 
Hutner’s trace solution (C. reinhardtii research center) and 150 µg/mL ampicillin [149, 150]. 
The cells were grown in sterile conditions with constant 125 rpm shaking, 200–300 µmols 
m−2·s−1 of cool white light at room temperature. They were harvested in mid-log phase at 
OD750 = 0.5 by centrifugation at 3500 rpm and 4 °C (Allegra 25R, Beckman Coulter, Brea, 
CA, USA). The wet biomass was stored at −80 °C. 
2.2.2 Recombinant E. coli Strain and Cultivation 
E. coli strain BL21 was modified to express bovine OPN with an N-terminal FLAG 




Center of Algae Biotechnology, UCSD. The recombinant strain was ampicillin resistant 
and OPN expression was controlled by the arabinose promotor.  
1 mL glycerol stock of the recombinant strain was used to grow overnight 
inoculum (5 mL) in Luria-Bertani (LB) media (150 µg/mL ampicillin) at 37 °C and 200 
rpm. The overnight inoculum was transferred to 1 L Terrific Broth (Sigma-Aldrich, St. 
Louis, MO, USA, Cat # T0918) and E. coli cells were grown at 37 °C, 200 rpm to OD600 
= 0.8. OPN expression was induced overnight with 0.2% (w/v) arabinose at 37 °C and 200 
rpm. The wet biomass was harvested by centrifugation and stored at −80 °C. 
2.2.3 Batch Adsorption Chromatography and Purification Studies  
Frozen biomass was thawed to room temperature and suspended in 1 g biomass:10 
mL lysis buffer (50 mM Tris, 150 mM NaCl, 1 mM EDTA, pH 7.4) containing protease 
and phosphatase inhibitor cocktail pills (Roche, Mannheim, Germany). Cells were lysed 
by sonication (15 min for C. reinhardtii and 5 min for E. coli) in 30 s on/off intervals at 4 
°C using a sonicator (Sonifier 250, Branson, Danbury, CT, USA) at 30% output control 
and 30% duty cycle with a micro probe (1/8” micro tip A3-561 Branson, Danbury, CT, 
USA). Cell lysates were centrifuged (10,000× g for 20 min at 4 °C, Allegra 25R centrifuge, 
Beckman Coulter, Brea, CA, USA) and cell-free supernatants were filtered through 0.22 
µm sterile polyethersulfone membrane syringe filter (30 mm diameter, Genesee Scientific, 
San Diego, CA, USA) and this was considered the clarified lysate for chromatography 
experiments. Protease and phosphatase inhibitor cocktail pills (Roche, Mannheim, 
Germany) in their recommended concentrations were added to all buffers used in the 




FLAG-affinity chromatography- FLAG-affinity purification was used to obtain 
highly purified recombinant OPN for analysis. 1 mL of anti-FLAG affinity gel (Sigma-
Aldrich, St. Louis, MO, USA, Cat # A4596) was equilibrated in lysis buffer for 30 CV 
and mixed with 5 mL of C. reinhardtii clarified lysate or 1 mL of E. coli clarified lysate. 
Incubation of resin and lysate was carried out for 2 h at 4 °C with continuous end-over-
end mixing in a Glas-Col rotor (Glas-Col LLC, Terre Haute, IN, USA) at ~33 rpm (40% 
speed control). The resin was separated from the clarified lysate by centrifuging at 6000× 
g for 5 min and the resin was loaded on a Bio Spin disposable chromatography column 
(Bio-Rad, Hercules, CA, USA, Cat # 732-6008). Non-specifically bound proteins were 
removed by washing with 10 CV of 50 mM Tris, 150 mM NaCl, 1 mM EDTA, pH 7.4. 
Proteins bound to resin were eluted using 5 CV of 100 mM Glycine, 400 mM NaCl, pH 
3.5. The pH of the eluted proteins was immediately raised to 8.0 by adding 50 µL of 1 M 
Tris-HCl, to avoid protein denaturation at low pH. 
Ceramic hydroxyapatite chromatography- Clarified lysates were dialyzed against 
5 mM sodium phosphate (NaP) pH 6.8 for 2 h at 4 °C using snake-skin membrane (3.5 
kDa molecular weight cut-off, Thermo Fisher Scientific, Waltham, MA, USA, Cat 
#68035). The clarified lysate (2.5 mL of C. reinhardtii clarified lysate, 0.66 mL of E. coli 
clarified lysate) was incubated for 1 h at room temperature by end-over-end mixing with 
0.5 mL of ceramic hydroxyapatite resin (Bio-Rad, Hercules, CA, USA, Cat # 1584000) 
pre-equilibrated in 5 mM NaP pH 6.8 and resin was loaded on a chromatography column. 




a step-wise increasing concentration (100 mM, 250 mM, 500 mM, 1000 mM and 1500 
mM) of NaP buffers at pH 6.8 with 5 CV of each buffer concentration. 
Immobilized Metal Affinity Chromatography (IMAC)- Gallium chloride at 400 
mM concentration was immobilized on Chelating Sepharose FF (GE Healthcare Life 
Sciences, Marlborough, MA, USA, Cat # 17-0575-01) as per manufacturer instructions 
and equilibrated with 50 mM MES, 500 mM NaCl pH 5.5. The C. reinhardtii and E. coli 
lysates were dialyzed against 50 mM MES, 500 mM NaCl pH 5.5 for 2 h at 4 °C using 
snake-skin membrane (3.5 kDa molecular weight cut-off). The dialyzed sample (2.5 mL 
of C. reinhardtii clarified lysate, 0.66 mL of E. coli clarified lysate) was incubated with 
0.5 mL of Ga-IMAC resin for 1 h at room temperature and loaded on a chromatography 
column. The resin was washed with 10 CV of 50 mM MES, 0.5 M NaCl pH 5.5, followed 
by protein elution using a step-wise increasing concentration (100 mM, 250 mM, 500 mM, 
1000 mM and 1500 mM) of NaP buffers with 5 CV of each buffer concentration. 
Anion-exchange chromatography- The clarified lysates were dialyzed against 50 
mM Tris pH 7.0 for 2 h at 4 °C using snake-skin membrane (3.5 kDa molecular weight 
cut-off), to bring the conductivity to 4 mS. The dialyzed samples (2.5 mL of C. reinhardtii 
clarified lysate, 0.66 mL of E. coli clarified lysate) were incubated for 1 h at room 
temperature by end-over-end mixing with 0.5 mL of Capto Q resin (GE Healthcare Life 
Sciences, Marlborough, MA, USA, Cat # 17-5316-10) equilibrated in 50 mM Tris pH 7.0. 
The resin was separated by centrifuging at 6000× g for 5 min and loaded on a 
chromatography column. The resin was washed with 10 CV of 50 mM Tris pH 7.0, 




300 mM, 500 mM, 1000 mM) of NaCl in 50 mM Tris pH 7.0 with 5 CV of each buffer 
concentration. 
2.2.4 Analytical Methods 
All total protein measurements were calculated using Bradford assay (Coomassie 
plus Assay kit, Thermo Fisher Scientific, Waltham, MA, USA, Cat #23236) on a 
microtiter plate format with bovine serum albumin (BSA) as standard. The absorption was 
measured at 595 nm using VersaMax microplate reader (Molecular Devices, San Jose, 
CA, USA). 
Proteins in sample were visualized and quantified using SDS-PAGE under 
reducing conditions. Denatured protein sample was loaded on NuPAGE Novex 4-12% 
Bis-Tris pre-cast gradient gels (Thermo Fisher Scientific, Waltham, MA, USA, Cat # 
NP0335BOX). The proteins were separated by electrophoresis for 35 min at constant 200 
V. All proteins were visualized by SimplyBlue SafeStain Coomassie G-250 stain (Thermo 
Fisher Scientific, Waltham, MA, USA, Cat # LC6065). ImageJ software (v.1.49, U. S. 
National Institutes of Health, Bethesda, MD, USA) was used to calculate purity of proteins 
in each sample lane. 
Anti-FLAG western blots were prepared by transferring protein bands from SDS-
PAGE gels onto a nitrocellulose membrane using iBLOT transfer kit (Thermo Fisher 
Scientific, Waltham, MA, USA, Cat # IB401002) for 7 min. The membrane was blocked 
with 2.5% non-fat milk in 0.05% TBS-T for 1 h and washed 3× with 0.05% TBS-T. The 
blocked membrane was then incubated with anti-FLAG M2 alkaline phosphatase 




1:2000 in 0.05% TBS-T for 1 h at room temperature on a gel rocker. The antibody solution 
was washed 3× with 0.05% TBS-T and developed for 2 min using a solution of NBT/BCIP 
developer pills (Sigma-Aldrich, St. Louis, MO, USA, Cat # B5655) dissolved in 10 mL 
of distilled water. Standard curves with FLAG-affinity purified OPN were used to estimate 
OPN concentrations when necessary. ImageJ software (v.1.49, National Institutes of 
Health, Bethesda, Maryland, MD, USA) was used to calculate relative amounts (%) of 
OPN in the fractions generated during adsorption chromatography experiments, 
normalized by the amount of OPN in the lysate. The 45 kDa and fragments of OPN were 
all included in calculating the amount of OPN in each fraction. Rubisco subunits were 
confirmed using similar western blotting protocol. Anti-Rubisco large and small subunit 
polyclonal antibodies (Agrisera antibodies, Vännäs, Sweden) were used as primary 
antibodies (1:5000) and anti-rabbit-alkaline phosphatase (Sigma-Aldrich, St. Louis, MO, 
USA) as secondary antibody (1:5000). 
Direct ELISA was used to determine OPN concentration in E. coli samples using 
FLAG-BAP (Sigma-Aldrich, St. Louis, MO, USA, Cat # P7582) as standards. Samples 
were diluted in phosphate buffer saline (PBS) and incubated overnight at 4 °C on Nunc 
immunosorbent 96-well plates. After 3 washes with PBS-T, blocking solution of 0.3% 
BSA in PBS was added to the 96-will plate and incubated for 2 h at 37 °C followed by 
similar wash and incubation with anti-FLAG M2 antibody conjugated with horse radish 
peroxidase (Sigma-Aldrich, St. Louis, MO, USA, Cat # A8592) diluted 1:5000 in PBS. 
TMB developer (Sigma-Aldrich, St. Louis, MO, USA, Cat # T0440) was used to develop 




FLAG-affinity purified OPN samples at 50 µg/mL concentration were analyzed 
for their pI and molecular weight using 2D gel electrophoresis performed by Protein 
Chemistry Lab, Texas A&M University, USA. pI resolution was performed with 
immobilized pH gradient technology (IPG Dry Strip, GE Healthcare Life Sciences, 
Marlborough, MA, USA) followed by electrophoresis on GE Healthcare Tall Mighty 
Small system (8 × 10 cm). The resolved gel was silver stained to visualize OPN and 
specificity was confirmed by anti-FLAG western blot. The pI values of OPN were 
estimated using the standard curve established by the IPG Dry Strip manufacturer. 
Phosphostaining was performed on FLAG-affinity purified OPN samples that 
were de-salted and de-lipidated by chloroform-methanol precipitation [151]. SDS-PAGE 
was performed as above and the gel was incubated in fixing solution (50% methanol, 10% 
acetic acid and 40% MilliQ water) overnight at room temperature on the gel rocker. The 
gel was washed 3× with MilliQ water and stained with Pro-Q diamond phosphostain 
(Thermo Fisher Scientific, Waltham, MA, USA, Cat # MPP33301) for 90 min in the dark. 
Destaining solution (20% acetonitrile in 50 mM sodium acetate pH 4.0) was added 3× 
with 30 min incubation each and the gel was finally washed 4× with MilliQ water. Gel 
imaging was performed on Typhoon Trio fluorescent imaging system (GE Healthcare Life 






2.3 Results and Discussion 
2.3.1 Expression and Characterization of Recombinant Osteopontin in C. reinhardtii 
and E. coli 
The transgenic cells of C. reinhardtii and E. coli expressing OPN were created by 
Mayfield’s group at California Center of Algae Biotechnology, University of California 
San Diego (UCSD) [148] and biomass was grown at Texas A&M University. 
Quantification of OPN concentration in C. reinhardtii lysates was difficult because of the 
low expression levels and interference of lysate components with enzyme-linked 
immunosorbent assay (ELISA). In the absence of a reliable quantification method, we 
relied on band density analysis of western blots with ImageJ software (v.1.49, U. S. 
National Institutes of Health, Bethesda, MD, USA), using FLAG-affinity purified OPN as 
a standard. C. reinhardtii OPN expression levels varied between biomass batches and was 
on average 4× lower than OPN in E. coli cells, as indicated by similar band densities of 
4× and 16× diluted C. reinhardtii and E. coli cell lysates, respectively (Figure 2.1, lanes 2 
& 3). In terms of initial OPN concentration expressed as a percent of total soluble protein 






Figure 2.1 Anti-FLAG western blots showing N-terminal fragments of osteopontin 
(OPN). Lane 1. Molecular weight (MW) marker, lane 2. C. reinhardtii lysate diluted 4×, 
lane 3. E. coli lysate diluted 16× 
 
Full-length recombinant OPN migrated to an apparent molecular weight of 45 kDa. 
This observation was consistent with the varied molecular weight (75–44 kDa) of OPN 
reported in literature and was attributed to the highly acidic nature of the protein [59, 76]. 
OPN expressed in the chloroplast of C. reinhardtii (Lane 2) consists of a major 45 kDa 
band and an N-terminal 35 kDa fragment. In addition to the 45 kDa band, E. coli lysate 
(Lane 3) contains several N-terminal fragments with apparent molecular weights 
corresponding to 40, 38, 35, 30 and 28 kDa. There were considerably fewer N-terminal 
fragments observed in algal lysates as compared to E. coli, suggesting that OPN is better 
protected from fragmentation in the chloroplast of C. reinhardtii than in the E. coli cytosol.  
The FLAG-affinity-purified E. coli and C. reinhardtii OPNs were analyzed by 2D 
electrophoresis gel (Figure 2.2) to estimate pI of various OPN forms. The 45 kDa OPN 
from C. reinhardtii resolved in a pI range from pH 3.5 to pH 4.5. A similar streak of 




suggest the presence of OPN isoforms that are likely due to heterogeneous post-
translational phosphorylation and/or in vitro enzymatic de-phosphorylation. In contrast, 
E. coli 45 kDa OPN resolved into a spot localized at pH 4.5. The E. coli OPN fragments 
were also localized at approximately the same pH 4.5. Single spots instead of streaks of 
E. coli OPN is consistent with the expected lack of protein phosphorylation in E. coli [152-




Figure 2.2 2D gel electrophoresis of OPN from transgenic (a) C. reinhardtii and (b) E. 
coli lysates obtained by FLAG-affinity purification 
 
The presence or absence of phosphorylation on the recombinant OPN was detected 
by phosphostaining an SDS-PAGE gel (Figure 2.3). The stained band in lane 4 indicates 
that the FLAG-affinity purified 45 kDa OPN from C. reinhardtii is phosphorylated, while 
its counterpart from E. coli in lane 5 is not stained and, thus, not detectable. The 




phosphorylated protein marker. The absence of phosphostaining of the 35 kDa band may 
indicate little or no phosphorylation. 
 
 
Figure 2.3 Pro-Q diamond phosphostained gel of OPN. Lane 1. MW marker, lane 2. C. 
reinhardtii lysate, lane 3. E. coli lysate, lane 4. Recombinant OPN purified from C. 
reinhardtii, lane 5. Recombinant OPN purified from E. coli. Each lane contains the same 
amount (~50 µg) of total soluble protein (TSP) 
 
The detection of phosphorylated residues in algal 45 kDa OPN provided 
motivation to look into the specificity of algal OPN interaction with ceramic 
hydroxyapatite (CHT) and immobilized transition metal (Ga, Fe, Zn) resins. 
2.3.2 Ceramic Hydroxyapatite Chromatography 
The results from equilibrium adsorption of OPN to CHT resin from clarified C. 








Figure 2.4 OPN distribution in fractions obtained with ceramic hydroxyapatite (CHT) 
resin (a) with no salt; (b) with 250 mM NaCl. Step elutions were performed with 
sodium phosphate (NaP) buffer, pH 6.8. Data (% OPN) were generated by ImageJ 
analysis of anti-FLAG western blots and normalized by the amount in the lysate. Error 
bars indicate standard deviation of triplicate ImageJ measurements 
 
The adsorbed E. coli and C. reinhardtii OPN, respectively, were eluted using 
increasing strength (100 to 1500 mM) of NaP buffer. The bar graph in Figure 2.4a reveals 


































absence of salt. The relatively low amount of C. reinhardtii OPN detected in the 
supernatant (30%) and its absence in the wash fractions indicates strong interactions 
between OPN and CHT. The bound C. reinhardtii OPN began to elute with 100 mM NaP 
and continued eluting through 1000 mM phosphate concentration. A significant fraction 
of adsorbed OPN eluted with the 250 mM (18%) and 500 mM NaP (33%) steps, 
respectively. Since we could not close the mass balance on OPN in the eluted fractions, 
even after 5 column volumes (CV) elution with 1500 mM NaP, we resorted to harsher 
desorption conditions using 100 mM NaOH. The strongly adsorbed OPN, estimated at 
41% of initial OPN by ImageJ analysis, was completely eluted with 100 mM NaOH. 
Western blots (Figure 2.5b) show that the 35 kDa fraction was eluted with 100 mM NaP 
and that the 45 kDa form interacted even more strongly, requiring higher phosphate 






Figure 2.5 (a) SDS-PAGE and (b) Anti-FLAG western blot of C. reinhardtii lysate 
binding and elution profile from ceramic hydroxyapatite (CHT) resin without 250 mM 
NaCl. All samples diluted to <1 mg/mL TSP. Lane 1: MW marker, lane 2. Clarified lysate, 
lane 3. Supernatant, lane 4. Washes 3 column volumes (CV), lane 5. Elution with 100 mM 
NaP, lane 6. Elution with 250 mM NaP, lane 7. Elution with 500 mM NaP, lane 8. Elution 
with 1000 mM NaP, lane 9. Elution with 1500 mM NaP, lane 10. Elution with 100 mM 
NaOH. All elutions were performed with 5 CV of the respective buffer 
 
As the bar graph in Figure 2.4a indicates, about 23% of E. coli OPN remained in 
the supernatant and 3% was found in the wash fractions. In contrast to C. reinhardtii, 72% 
of E. coli OPN eluted from hydroxyapatite resin in the 100-500 mM phosphate buffer 
range. As expected from the mass balance of OPN fractions eluted with the three NaP 
steps changes, the application of 100 mM NaOH did not yield a significant amount of 
OPN (only 8% of initial amount). The significant difference in the amount of 45 kDa OPN 
eluted with 100 mM NaP (7% algal OPN consisting of mainly 35 kDa OPN vs. 11% of E. 
coli 45 kDa OPN) and 100 mM NaOH (41% algal OPN vs. 8% E. coli OPN) steps indicate 
that E. coli and C. reinhardtii OPN interact differently with heterogeneous binding sites 
of CHT resin. 
To determine if the different interaction strengths of OPN with CHT were due to 




OPN, the adsorption and elution experiments were repeated in the presence of 250 mM 
NaCl (Appendix Figure A1). The inclusion of 250 mM NaCl in the adsorption and elution 
buffers was intended to reduce ionic interactions of amino acid side chains of OPN with 
Ca2+ and PO4
3− sites on the CHT without disrupting the much stronger coordinate bonding 
between OPN’s phosphoryl groups and Ca2+ on CHT surface. The results shown in Figure 
2.4b clearly demonstrate a difference in the adsorption of E. coli and C. reinhardtii OPN 
in the presence of salt. About 83% of E. coli OPN remains in the supernatant at the end of 
the adsorption period compared to the barely detectable amount (~1%) OPN in C. 
reinhardtii supernatants. An additional 10% of E. coli OPN was removed in the wash step 
while none of C. reinhardtii OPN was desorbed during the washing. Comparison of the 
data presented in Figure 2.4 demonstrates that the adsorption of E. coli OPN to CHT was 
significantly weakened by 250 mM NaCl, whereas that of C. reinhardtii was not. The 
latter, somewhat atypical behavior of increased C. reinhardtii OPN binding, can be 
explained by NaCl suppression of electrostatic repulsions between phosphoryl groups on 
OPN and PO4
3− sites on the CHT [155]. The suppression of electrostatic repulsions, results 
in enhanced interactions between algal OPN’s phosphoryl groups with the Ca2+ on CHT 
surface.  
Therefore, E. coli OPN probably binds to hydroxyapatite by electrostatic 
interactions as depicted in Figure 2.6 below. This observation is consistent with the 
reported multi-modal interaction of proteins with CHT via charge interactions between 
acidic and basic amino acid side chains with the Ca2+ and PO4
3− moieties on CHT, 





Figure 2.6 Putative multimodal interaction mechanisms of OPN with ceramic 
hydroxyapatite (CHT) resin at pH 6.8. Basic (arginine, histidine and lysine) amino acids 
of OPN are shown in blue, phosphoryl groups in yellow and acidic (aspartic and 
glutamic acid) in red 
 
Based on these data, we believe that protein phosphorylation made a difference in 
the interaction of OPN with ceramic hydroxyapatite resin for the following reasons. First, 
compared to E. coli OPN, the addition of NaCl had a minimal or no measurable effect on 
C. reinhardtii OPN adsorption and elution from CHT (Figure 2.4). The presence of NaCl 
weakens E. coli OPN interaction with CHT as evidenced by 83% of OPN remaining 
unbound in supernatant and the residual 17% being desorbed during wash and first step 
100 mM NaP step (Figure 2.4b). Second, the elution of C. reinhardtii OPN, irrespective 
of ionic strength, required displacement by increasing phosphate concentration and 
complete desorption of phosphorylated OPN by the application of 100 mM NaOH. This 
line of evidence suggests that C. reinhardtii OPN adsorption to CHT is mediated by the 
stronger Ca2+–PO3
2− coordinate binding rather than simple charge interactions. And, the 




mM NaOH for elution (Figure 2.4b), is probably the result of interaction of multiple, 
closely positioned phosphoryl (PO3
2−) groups on OPN molecule with calcium moieties 
(Ca2+) of CHT resin. 
To assess the specificity and purification capability of CHT, we compared host 
protein binding and elution by SDS-PAGE (Figure 2.5a). Data in Figure 2.5a indicate that 
a significant number of algal proteins would co-elute with OPN. The major OPN 
“competitor” appears to be acidic, phosphorylated chloroplast protein, Rubisco [156], as 
large (~50 kDa) and small subunit (~15 kDa) can be seen in 1000 mM NaP and 100 mM 
NaOH fractions (Figure 2.5a, lane 8 and 10 respectively). The identity of Rubisco was 
confirmed by western blots using anti-Rubisco large and small subunit antibodies 
(Appendix Figure A3). Thus, the presence of Rubisco in C. reinhardtii lysates would 
eventually reduce the resin breakthrough capacity and OPN purification fold, both of 
which are important factors in process scale-up. A possible solution to CHT application 
for OPN purification is to remove Rubisco and other interfering host protein impurities 
from the clarified lysates before OPN binding to CHT. 
2.3.3 Gallium-Immobilized Metal Affinity Chromatography (Ga-IMAC) 
Gallium, iron and zinc immobilized on Chelating Sepharose are known to bind 
phospho-peptides by coordinate bonds [157-159]. Gallium, having higher affinity than 
other metals for phosphorylated peptides [160], has been selected in this study to 
determine if differential interactions between Ga3+ and phosphorylated protein residues 
could be utilized for the separation of C. reinhardtii OPN from non-phosphorylated 




interactions due to phosphorylation. To eliminate any ionic interactions between the 
protein and Ga-IMAC resin, OPN adsorption and elution was tested in the presence of 150 
mM and 500 mM NaCl. Results from Ga-IMAC batch adsorption chromatography are 
shown in Figure 2.7. Approximately 20% of C. reinhardtii OPN remained unbound in the 
supernatant compared to only 7% of E. coli OPN. An additional 8% of algal OPN was 
removed during the resin wash step. The majority of the unbound and wash fractions 
contained 35 kDa form of algal OPN (Appendix Figure A2) which, as discussed above, 
did not bind strongly to CHT either. The adsorbed C. reinhardtii OPN started to elute with 
100 mM NaP with 8-12% of 45 kDa OPN continuing to elute in each step elution up to 
1000 mM NaP concentration. The major fraction (21%) of bound E. coli OPN was in the 
second step elution with 250 mM NaP (Figure 2.7). The remaining bound E. coli OPN 
was eluted with 500 and 1000 mM NaP.  
The binding mechanism of C. reinhardtii OPN to Ga-IMAC apparently does not 
involve phosphorylated residues because non-phosphorylated E. coli OPN binds and 
elutes similarly to phosphorylated C. reinhardtii OPN (Figure 2.7). In addition, the similar 
binding and elution profiles observed with Fe-IMAC resin suggests that OPN interacts 
with Ga3+ and Fe3+ via the multiple carboxylic acidic containing amino acids occurring in 
close proximity (carboxyl clusters) present in both E. coli and C. reinhardtii OPN. 
Unfortunately, we could not confirm this hypothesis because adsorption at or below pH 
4.5 (pKa of carboxyl groups) was not possible due to OPN precipitation at that pH range. 
Based on our data, it appears that protein interactions with transition metals (Ga3+ or Fe3+) 




Ga-IMAC resin would not be useful for the separation of C. reinhardtii OPN from other 
acidic algae proteins present in the lysates. 
 
 
Figure 2.7 OPN distribution in fractions obtained with Ga-IMAC resin. Adsorption and 
elution was done in the presence of 500 mM NaCl. Step elutions were performed with 
sodium phosphate (NaP) buffer, pH 5.5. Data (% OPN) were generated by ImageJ analysis 
of anti-FLAG western blots and normalized by the amount in the lysate. Error bars indicate 
standard deviation of triplicate ImageJ measurements 
 
2.3.4 Anion Exchange Chromatography 
Previous studies with E. coli OPN have used anion exchange chromatography as 
one of the purification steps [96, 97]. The use of anion exchange adsorption is a natural 
choice for highly acidic proteins like OPN. We decided to compare the interaction of C. 
reinhardtii and E. coli OPN with a strong anion exchange resin (Capto Q, GE Healthcare 
Life Sciences, Marlborough, MA, USA). The analysis of binding and elution pools of 




























(Figure 2.9). When bound at pH 7.0 and a low conductivity of 4 mS, OPN bound strongly 
and specifically to the resin. No C. reinhardtii OPN (<1%) was detected by western blot 
in the supernatants and the washes (Figure 2.8). The majority of C. reinhardtii 35 kDa 
OPN fragment, which constitutes 11% total OPN was eluted with 100 mM NaCl (Figure 
2.9a lane 5) suggesting weaker interaction with the quaternary amine than the intact 45 
kDa form. The 45 kDa OPN from C. reinhardtii eluted in 200–500 mM NaCl range 
reaching a peak concentration in the 300 mM NaCl elution fraction. A faint band (~1.4%) 
was also observed with 1000 mM NaCl elution (Figure 2.9a lane 9). E. coli OPN also 
bound on anion exchange column strongly, demonstrated by the lack of a band in the 
supernatant and washes (Figure 2.9b lane 3 and 4). The elution of intact 45 kDa E. coli 
OPN starts earlier than algal OPN, with 16% in 100 mM NaCl elution (Figure 2.9b, lane 
5) and elution continues till 500 mM NaCl with the highest concentration (37%) at 300 
mM NaCl elution similar to C. reinhardtii OPN. The elution region for E. coli OPN is 
narrower under the same conditions with very little to no OPN over 500 mM NaCl elution. 
This observation corresponds to the 2D gel electrophoresis results, where E. coli OPN 
fragments were localized to spots, reflecting homogenous pI that should result in a uniform 
binding strength to the Capto Q resin. C. reinhardtii OPN had horizontal streaks on the 
2D gel indicating a broader pI range of OPN due to heterogeneous phosphorylation. 
Hence, the elution profile of the adsorbed OPN would require a broader range of salt 
concentration to break the “heterogeneous” strength interactions with the resin. The ionic 








Figure 2.8 OPN distribution in fractions obtained with strong anion exchange resin (Capto 
Q). Step elutions were performed with sodium chloride in 50 mM Tris pH 7.0. Data (% 
OPN) were generated by ImageJ analysis of anti-FLAG western blots and normalized by 

































Figure 2.9 Anti-FLAG western blot of (a) C. reinhardtii (b) E. coli OPN binding and 
elution profile from Capto Q (strong anion exchange) resin. All samples diluted to <1 
mg/mL TSP. Lane 1. MW marker, lane 2. Clarified lysate, lane 3. Supernatant, lane 4. 
Washes (3 CV), lane 5. Elution with 100 mM NaCl, lane 6. Elution with 200 mM NaCl, 
lane 7. Elution with 300 mM NaCl, lane 8. Elution with 500 mM NaCl, lane 9. Elution 
with 1000 mM NaCl. All elutions were performed with 5 CV of the respective buffer 
 
SDS-PAGE (Figure 2.10) reveals that partial separation of OPN from C. 
reinhardtii host protein by anion exchange chromatography is possible. The majority 
(>99%) of recombinant algal OPN was adsorbed on the resin, about 49% of the host 
protein was present in the supernatant (lane 3) and wash fractions (lane 4) while the rest 
of the host protein was co-adsorbed with OPN. The majority of host protein was eluted in 
100–300 mM NaCl fractions (lanes 5–7), whereas, OPN eluted in 200–500 mM NaCl 
fractions (lanes 6–8). Thus, by pooling 200 to 500 mM NaCl elution fractions at least 
forty-fold increase of OPN purity (from 0.2% to 8% TSP) and 80% recovery can be 
achieved by anion exchange chromatography. The anion exchange data also demonstrate 
that a substantial fraction of phosphorylated host protein (Rubisco), which was identified 




separated from OPN by excluding the 200 mM NaCl elution and pooling only the 300 and 
500 mM fraction for further OPN isolation. In the latter case, OPN purity would increase 
to 20% at the expense of reduced recovery (~60%) as calculated from Figure 2.10. 
 
 
Figure 2.10 SDS-PAGE of C. reinhardtii lysate binding and elution profile from Capto Q 
(strong anion exchange) resin. All samples diluted to <1 mg/mL TSP. Lane 1. MW marker, 
lane 2. Clarified lysate, lane 3. Supernatant, lane 4. Washes (3 CV), lane 5. Elution with 
100 mM NaCl, lane 6. Elution with 200 mM NaCl, lane 7. Elution with 300 mM NaCl, 
lane 8. Elution with 500 mM NaCl, lane 9. Elution with 1000 mM NaCl. All elutions were 
performed with 5 CV of the respective buffer 
 
2.3.5 Two-Step Purification of OPN by Capto Q and CHT Chromatography 
The proposed two-step process was tested by capturing OPN and removing C. 
reinhardtii impurity proteins using anion exchange, Capto Q resin followed by separation 
of phosphorylated osteopontin by mixed-mode CHT resin. Anion exchange 




both fragments were separated from OPN in the 200 mM NaCl. Resolving acidic host cell 
impurities from the OPN containing fractions, reduces the protein load on CHT 
chromatography and minimizes interference of acidic species with selectivity of 
phosphorylated proteins. Capto Q elution fractions containing OPN, 300 mM and 500 mM 
NaCl buffer eluates were pooled, they contained OPN at 23% purity and 63% yield (Figure 
2.10). This elution pool was conditioned by dialysis and brought to the binding condition 
of pH 6.8 containing 250 mM NaCl. Batch chromatography with CHT resin was 
performed and OPN was eluted with increasing concentrations of NaP. Table 2.1 shows 
the distribution of OPN in the elution fractions, and the purity of each step elution. OPN 
was completely bound to CHT resin and 13% of OPN started eluting with 100 mM NaP 
buffer at 23% purity. Since this fraction purity was similar to the Capto Q elution pool 
purity (23%), it was not included in the CHT elution pool. Elutions fractions from 250 
mM - 1000 mM NaP buffer contained 33% of OPN bound to CHT at a high purity of 75%. 
This was a remarkable 375-fold increase from the lysate purity of 0.2%. This increased 
selectivity of OPN was possible due to successful removal of interfering acidic impurities 
using Capto Q resin as the capture chromatography. The current recovery of 33% is not 
ideal, but the losses are exacerbated by the heterogeneous isoforms of OPN interacting 





Table 2.1 Recovery and purity of OPN from two-step purification by Capto Q and CHT 
chromatography 
Sample Elution fraction % Purity % Recovery 
% Purity of 
selected 
elution pool 




lysate  - 100   
Capto Q  
300 mM–500 
mM NaCl   23.5 61 
CHT  
100 mM NaP 22.7 13   
250 mM NaP 68.7 13 
75 33% 
500 mM NaP 58.3 12 
1000 mM NaP 99 8 
1500 mM NaP - 0   
100 mM NaOH 41.7 4   
 
2.4 Conclusions 
Osteopontin was successfully expressed in the chloroplast of C. reinhardtii, a 
novel alternative platform for recombinant protein production, capable of performing 
phosphorylation as a post-translational modification. The C. reinhardtii strain expressed 
two major OPN isoforms (45 kDa and 35 kDa) with pI ranging from 3.5 to 4.5 due to 
heterogeneous post-translational phosphorylation.  
Several chromatography resins were evaluated for isolating OPN by utilizing 
interactions with the phosphorylation and the unique polyaspartate sequence. Ceramic 
hydroxyapatite resin demonstrated affinity for acidic and phosphorylated proteins and 
adsorbed the phosphorylated OPN (45 kDa) isoform strongly. The adsorption and co-
elution of phosphorylated host proteins like Rubisco along with C. reinhardtii OPN, 




between major phosphorylated impurities (Rubisco) and OPN, it is not ideal for separation 
of phosphorylated recombinant proteins from C. reinhardtii. 
Gallium-IMAC, did not exhibit a preferential binding of phosphorylated OPN. 
Both phosphorylated OPN from C. reinhardtii and non-phosphorylated OPN from E. coli 
appeared to have similar binding and elution behavior with Ga-IMAC. Our study suggests 
that Ga3+ interacts with multiple carboxyl groups of OPN and host proteins and has no 
specific preference for the phosphorylated algal OPN 45 kDa form. As such, Ga-IMAC 
resin does not offer any advantage over CHT as a potential purification method for 
phosphorylated OPN forms.  
Anion exchange chromatography is a viable adsorption step for capturing OPN 
from both E. coli and C. reinhardtii clarified lysates. The anion exchange chromatography 
conducted under optimal adsorption, resin-wash and elution conditions removes as much 
as 50% of host protein while maintaining OPN recovery yield at 80%. Other anionic 
protein impurities bound to the resin can be partially separated from OPN based on their 
strength of charge interactions with the amine ligand resulting in a 20% pure OPN fraction. 
The suggested purification process of anion exchange chromatography followed 
by mixed-mode CHT chromatography was performed and phosphorylated OPN at 75% 
purity was obtained. The process recovery was 33%, further efforts to increase the purity 
were not undertaken due quantification limitations that stem from poor expression titers.  
Because of low accumulation levels in our current C. reinhardtii strain leading to 










EXPLORING THE SEPARATION POWER OF MIXED-MODAL RESINS FOR 
PURIFICATION OF RECOMBINANT OSTEOPONTIN FROM CLARIFIED E. COLI 
LYSATES* 
3.1 Introduction 
Osteopontin (OPN) is a structural protein essential for biomineralization process 
such as bone remodeling and kidney stone inhibition [161-164]. It is also recognized as a 
molecular marker for tissue disorders including cancer due to its role in cell signaling, 
adhesion, and migration in regular conditions and during stress responses [165, 166]. The 
prospective health benefit as a therapeutic as well as potential diagnostic and prognostic 
value have invigorated the development for an efficient and scalable downstream process. 
Recombinant OPN is a single-chain polypeptide composed of about 300 amino 
acids and it is highly acidic with an isoelectric point of 4.3 [167]. OPN is often categorized 
as an Intrinsically Disordered Protein (IDP) which is biologically active in a flexible form 
lacking a well-defined secondary and tertiary structure [168, 169]. OPN’s acidic 
isoelectric point, low expression level, flexible structure and the acidic nature of host cell 
proteins are challenges to the development of OPN purification methods that make the 
search for a suitable and efficient purification process vitally important. 
 
 
*Reprinted from Guo, S., Ravi A, Mayfield S, Nikolov ZL. Exploring the separation 
power of mixed‐modal resins for purification of recombinant osteopontin from clarified 
Escherichia coli lysates. Biotechnology Progress, 2018. Copyright 2018, with 




Despite the lack of post-translational phosphorylation, recombinant OPN from E. 
coli has made major contributions to OPN related research as it shows biological functions 
such as cell adhesion enhancement, cell proliferation activities, and cell migration 
improvement activities [96, 99].  
Various strategies have been attempted to purify OPN from recombinant E. coli 
lysates. Fusion tags such as Glutathione-S-transferase (GST) and Histidine (His) were 
widely applied for studying OPN biochemistry for their convenient purification by affinity 
chromatography [99, 147, 170]. These fusion protein methods produced micrograms of 
OPN for biochemical characterization without supplying data on yield and potential 
scalability. In general, tagged proteins are not desirable for manufacturing biotherapeutics 
as their removal increases regulatory burden, reduces process yield and results in higher 
operating cost. 
Non-tag methods for OPN purification from recombinant E. coli as well as native 
sources such as milk were also reported. Anion exchange chromatography is often used 
as the default method for OPN purification as its low isoelectric point allows strong 
binding [57, 92, 94]. The recently reported purification of mouse OPN expressed in E. coli 
is probably the most relevant analog for our work [96]. The cell-free lysate was 
fractionated using a series of isoelectric precipitation steps (pH 6, 5, and 4.3) followed by 
20% ammonium sulfate precipitation. The multiple precipitation steps increased OPN 
purity from 7% to 45%, but severely reduced OPN yield to 21%. A final OPN purity of 




followed by cation exchange chromatography. The overall OPN yield was a low 12.8% 
[96]. 
In our previous study focusing on microalgae-expressed OPN, we investigated the 
interaction of E. coli-expressed OPN and phosphorylated OPN from microalgae with 
ceramic hydroxyapatite (CHT, Bio-Rad) and strong anion exchange (Capto Q, GE 
Healthcare) resins [171]. Selectivity was observed when OPN bound to both resins from 
low-ionic strength lysates by charge interactions. At higher ionic strength (250 mM NaCl) 
only phosphorylated OPN bound to CHT presumably via (Ca2+ - PO3
2-) coordinate 
binding. Our preliminary studies with microalgae-expression indicated that OPN suffered 
from stability issues when exposed to 1.5 M ammonium sulfate which was required for 
efficient binding by hydrophobic interaction to Phenyl Sepharose FF (high-sub, GE 
Healthcare). 
The lack of orthogonality in reported processes and OPN’s poor salt stability in 
our hands led us to search for more efficient and scalable OPN purification methods 
employing mixed-modal resins. Mixed-modal adsorbants have received attention from 
process developers for their wide variety of chemistries that provide unique advantages 
over traditional single-mode chromatography [172]. Several reports have shown the 
potential application of mixed-modal resins as capture chromatography step for 
recombinant proteins expressed in E. coli. A purification process using HEA HyperCel 
(Pall) efficiently separated recombinant human granulocyte colony stimulating factor 
from host cell proteins and product-related impurities, which otherwise required three 




properties of HEA and PPA HyperCel resins were successfully utilized to purify 
recombinant allergen (rBet v 1a) and achieve 9-fold purification from “physiological-like” 
crude extract [173]. In another example, the combined action of the same two resins was 
superior to affinity purification of maltose-binding fusions from E. coli extracts [174]. Due 
to complex interactions of proteins with mixed-modal ligands, the screening of a wide 
range of conditions is often required to comprehensively evaluate ligand-protein 
interaction and identify the design space for process development [26, 35, 54, 175]. 
In this study, we used high-throughput screening (HTS) and batch adsorption 
experiments to obtain a better understanding of OPN interaction with three mixed-modal 
resins (Capto adhere, HEA HyperCel and PPA HyperCel) and select optimal adsorption 
and elution conditions. The latter conditions allowed us to propose a two-step purification 
process that maximizes OPN recovery and purification factor. 
3.2 Materials and Methods 
3.2.1 E. coli Cell Cultivation and Harvest 
The OPN recombinant E. coli strain was provided by Dr. Mayfield from University 
of California, San Diego. The construct was based on BL21-AI strain. The production of 
recombinant OPN was regulated by an arabinose inducible promotor. A FLAG fusion tag 
was added to the N-terminus of recombinant OPN for detection purposes. The construct 
contained an ampicillin resistance selective marker. 
The strain was kept as frozen stock cell bank in 25% glycerol at -80°C for long 




Miller’s Luria Broth (LB medium, Miller’s) (Sigma-Aldrich, L3522) with 150 µg/mL 
Ampicillin for plasmid selection and incubated at 37°C on an orbital shaker at 200 rpm 
for 5 hours as the seed culture. Five mL of the seed culture was then transferred to 1 L 
Terrific Broth (Sigma-Aldrich, T0918) with 50 µg/mL Ampicillin and incubated at 37°C 
and 200 rpm shaking until OD 600 reached 0.8. OPN protein production was induced by 
adding Arabinose to a final concentration of 0.2% (w/v). The cells were incubated on an 
orbital shaker at 37°C with 200 rpm overnight. The cells were harvested by centrifugation 
at 3,000 g for 10 minutes at 4°C. The harvested E. coli biomass was stored at -80°C until 
use. 
3.2.2 Cell Lysis and Protein Extraction 
The frozen biomass was suspended in lysis buffer (150 mM NaCl, 1 mM PMSF, 
50 mM Tris, pH 7.4) at 1:10 (w/v) ratio and lysed by sonication (QSonica, Q55) at 40% 
amplitude of 30 seconds on/off cycle in ice bath for 5 cycles. The cell debris was removed 
by centrifugation at 15,000 g for 30 minutes at 4°C. The supernatant was collected and 
further clarified by syringe filter of 0.22 µm pore size as clarified cell lysate, which served 
as the starting material of the chromatography studies. 
3.2.3 High-Throughput Screening (HTS) for Protein-Ligand Interaction Studies 
HTS experiment was performed to study the interaction between OPN and mixed-
modal ligands under different conditions. Salt concentration and pH were two factors to 
be tested and multiple levels of each factor were included in a full factorial design with 3 
replicates. The specific conditions tested were discussed in results and discussion. The pH 
73 
of the clarified cell lysate was adjusted with 0.2 M HCl or 0.2 M NaOH and salt 
concentration by adding solid NaCl to the cell lysate followed by mixing end-over-end on 
a test tube rocker (Thermolyne speci-mix, ThermoFisher Scientific) for 15 minutes at 
room temperature. At the end of the mixing period, clarified lysate was centrifuged at 
15,000 g for 30 minutes at 4°C to remove the precipitates. 
The resin slurry (50%) was dispensed in a 96-well filter plate (3M Empore), 0.05 
mL resin for each well. Storage buffer was removed by centrifugation at 300 g for 7 
minutes. Resin equilibration was achieved by adding 4 column volumes (0.2 mL each 
well) of loading buffer of designed adsorption conditions to the sorbents respectively, 
mixing gently for 10 minutes and then removed by centrifugation at 300 g for 7 minutes. 
The equilibration process was done twice before sample application. Conditioned cell 
lysate was loaded to the equilibrated resins (0.2 mL of lysate for each well) and the plate 
was sealed. The lysate-resin mixture was incubated with gentle vortex ensuring no visual 
settling of the resins for 1 hour at room temperature. The unbound sample was collected 
for analysis by centrifugation. 
3.2.4 Batch Adsorption Experiments for Resin Performance Evaluation 
Mixed-modal resins used in this study were Capto adhere purchased from GE 
Healthcare (Marlborough, MA, USA), HEA and PPA HyperCel from Pall (Port 
Washington, NY, USA). The ligand structure and primary adsorption chemistry are listed 
in Table 3.1. 
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Table 3.1 List of candidate mixed-mode resins for OPN purification 
The general procedure of batch adsorption experiment was as follows: Conditioned 
cell lysates were incubated with pre-equilibrated resins for 1 hour with end-over-end 
mixing at room temperature. The loading volume was set at 6 column volumes (CV; 1.2 
mL conditioned lysate load to 0.2 mL resin) for all the resins tested, equivalent to feeding 
about 30 mg total protein/mL resin. The lysate-resin mixture was then loaded on a 
PolyPrep column (Bio-Rad) and the unbound protein was collected by gravity as 
“Flowthrough”. The resin was washed with 10 CV of loading buffer. Adsorbed proteins 
were eluted using 10 CV of the appropriate elution buffer. All the samples were collected 
by gravity for analysis. The average gravity-driven linear velocity during elution was 
about 100 cm/h. The specific protocols designed for individual resins are listed below. 
HEA HyperCel low-salt batch adsorption and elution- HEA HyperCel low-salt 
binding condition was the same as the lysate condition (150 mM NaCl, 50 mM Tris, pH 
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7). No additional conditioning step was required. The clarified lysate was incubated with 
HEA HyperCel resin pre-equilibrated with binding buffer (150 mM NaCl, 50 mM Tris, 
pH 7) for 1 hour at room temperature. The lysate-resin mixture was then transferred into 
a PolyPrep Column and the flowthrough sample was collected by gravity. The resin then 
was washed by 20 CV binding buffer and the wash sample was also collected for further 
analysis. Protein elution was designed to be a 3-step process with 10 CV of each elution 
buffer. The first elution was achieved using 1 M NaCl, 50 mM Tris pH 7 buffer. The 
second elution was 1 M NaCl, 100 mM sodium acetate (NaAc) pH 5 buffer. The third 
elution buffer was 100mM sodium citrate buffer at pH 3 with no NaCl addition. 
HEA HyperCel high-salt batch adsorption and elution- A second binding condition 
tested for HEA HyperCel resin was at high salt concentration. Solid NaCl was added into 
clarified lysate to reach a final NaCl concentration of 3 M. After 15 minutes of end-over-
end mixing, the lysate was centrifuged at 15,000 g for 30 minutes to remove any 
precipitates. The conditioned lysate was then incubated for 1 hour at room temperature 
with pre-equilibrate HEA HyperCel resin by the high salt binding buffer (3 M NaCl, 50 
mM Tris, pH 7). The lysate-resin mixture was then transferred into a PolyPrep Column 
and the flowthrough sample was collected by gravity. The wash and elution procedure 
following HEA high salt batch adsorption was exactly the same as HEA low salt batch 
adsorption. 
PPA HyperCel low-salt batch adsorption and elution- The PPA low salt batch 
adsorption and elution experiment followed the same protocol as HEA low salt batch 
adsorption and elution experiment. 
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PPA HyperCel high-salt batch adsorption and elution- Similarly, the PPA low salt 
batch adsorption and elution experiment followed the same protocol as HEA high salt 
batch adsorption and elution experiment. 
Capto adhere batch adsorption and elution- The clarified lysate was conditioned 
by dialysis against 50 mM Tris buffer (pH 7) overnight at 4°C for salt removal using 
SnakeSkin dialysis tubing (MWCO = 3.5 kDa, ThermoFisher Scientific). The conditioned 
lysate was incubated with Capto adhere resin for 1 hour at room temperature by end-over-
end mixing. The lysate-resin mixture was then transferred to PolyPrep column (Bio-Rad) 
and the “flowthrough” sample was collected by gravity. The resin was washed by 20 CV 
of 50 mM Tris pH 7 binding buffer. Elution was designed to have 3 stages of descending 
pH change (pH 5, 4, and 3). All elution buffers were 0.1 M citrate-phosphate buffer with 
no extra salt addition. 
Capto Q (strong anion exchange) batch adsorption and elution- The experiments 
with Capto Q were performed using the same binding conditions and lysate conditioning 
used with Capto adhere resin. The resin was washed by 20 CV of 50 mM Tris pH 7 binding 
buffer. The elution was achieved in 3 steps with 50 mM Tris pH 7 buffer containing 0.2 
M NaCl, 0.5 M NaCl, and 1 M NaCl. 
3.2.5 Packed-Bed Purification of OPN 
Packed-bed chromatography and process optimization was performed using 
ÄKTA Purifier (GE Healthcare Life Sciences), and the top two resin performers, PRC 
HEA HyperCel and HiTrap Capto Q, were evaluated in prepacked column format.  PRC 
HEA HyperCel (1 mL) was purchased from Pall and HiTrap Capto Q (1 mL) from GE 
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Healthcare. The same feed composition and load volume as used in batch adsorption 
experiment was used on prepacked columns to allow for verification and comparison 
between batch adsorption and packed-bed chromatography trials. 
The general protocols for packed-bed chromatography in this research are as 
follows. The volumetric flow rate was controlled at 0.2 mL/min to ensure 5 minutes 
residence time during sample loading. The same linear velocity was used for the wash and 
elution steps. Protein concentration during chromatography and ionic strength of elution 
buffers was monitored continually by absorbance reading at 280 nm and conductivity 
measurement, respectively. Eluted fractions (1 mL) were collected in fraction collector 
(Frac-950, GE Healthcare Life Sciences) and analyzed for total protein by Bradford assay 
and OPN content by ELISA. The elution process was the subject to change and 
optimization on packed-bed chromatography. 
HEA HyperCel resin performance verification on prepacked column- Clarified 
lysate (in 150 mM NaCl, 50 mM Tris, pH 7 condition) was loaded onto the equilibrated 
PRC HEA HyperCel column (1 mL) and washed with 20 CV of binding buffer. Linear 
NaCl gradient (0.15 to 1.5 M NaCl over 20 CV) in 50 mM Tris pH 7 was applied as the 
elution process. The flow rate was controlled at 0.2 mL/min to ensure a 5 minute residence 
time for binding, and kept constant through wash and elution steps. 
Two-step purification of OPN by HEA HyperCel and Capto Q- Clarified lysate 
(150 mM NaCl, 50 mM Tris, pH 7 buffer) was directly loaded onto the equilibrated PRC 
HEA HyperCel column and washed with 20 CV of binding buffer. A single step change 
elution was used for OPN recovery from HEA. The elution buffer was 50 mM Tris pH 7 
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buffer containing 1 M NaCl. The first 8 CV of elution fraction was collected as the HEA 
purified pool. The partially purified OPN from HEA HyperCel elute was dialyzed against 
50 mM Tris pH 7 buffer overnight at 4°C for salt removal. Dialyzed HEA eluate 
(conductivity < 5 mS), was loaded on HiTrap Capto Q (1 mL) as previous protocols, 
washed with 20 CV of the binding buffer (50 mM Tris pH 7, 4 mS). After the wash 
procedure, 0–1 M NaCl linear gradient elution (20 CV) was applied to Capto Q for OPN 
elution. 
3.2.6 Analytical Methods 
Bradford assay for total protein determination- Total soluble protein was 
determined by Bradford assay in 96-well plates with bovine serum albumin (BSA) 
standards (Pierce™ Coomassie Plus (Bradford) Assay Kit, ThermoFisher Scientific) 
[176]. 
ELISA (enzyme-linked immunosorbent assay) for OPN quantification- The 
standards were prepared from FLAG-BAP (Sigma-Aldrich P7582) diluted in PBS. The 
samples were diluted in PBS and detected by anti-FLAG M2 antibody conjugated with 
HRP (Sigma-Aldrich A8592). 
SDS-PAGE and Western-blot for product quality measurement- The purified 
fractions were analyzed by SDS-PAGE (Invitrogen NuPAGE 4- 12% Bis-Tris Gel). The 
gels were stained for 3 hours (SimpleBlueTM Safe Stain, Novex). For Western-blotting, 
the protein was transferred to PVDF membrane (Invitrogen iBlot Gel Transfer Stacks, 
PVDF, mini) and detected by anti-FLAG M2 antibody conjugated with alkaline 




Resin performances evaluation- The OPN capture performances of candidate 
resins were evaluated by two major parameters—purification factor and OPN recovery. 
The fractions collected from batch adsorption and elution experiments were analyzed by 
Bradford assay for total protein concentration and ELISA for OPN concentration. The 
purity of clarified lysate and fractions from batch adsorption and elution experiments were 









Because Bradford assay responds differently to proteins with different amino acid 
compositions, it was less reliable for highly purified OPN samples where only a handful 
of protein species existed. Therefore, the purity of purified OPN after two-step purification 
was determined by analyzing the SDS-PAGE image with ImageJ software [177]. 
The recovery of each candidate resin was calculated by dividing the amount of 
OPN (mg) from the elution fraction with the majority of OPN by the amount of OPN from 
the conditioned cell lysate (feed). 
𝑅𝑒𝑐𝑜𝑣𝑒𝑟𝑦 =
𝑂𝑃𝑁 (𝑚𝑔) 𝑖𝑛 𝑡ℎ𝑒 𝑂𝑃𝑁 𝑒𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛
𝑂𝑃𝑁 (𝑚𝑔) 𝑖𝑛 𝑡ℎ𝑒 𝑓𝑒𝑒𝑑
× 100 
Purification factor of each candidate resin was defined as the ratio of purity of the 
elution fraction with the majority of OPN and the purity of the feed. 
𝑃𝑢𝑟𝑖𝑓𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 =
𝑃𝑢𝑟𝑖𝑡𝑦 𝑜𝑓 𝑡ℎ𝑒 𝑂𝑃𝑁 𝑒𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑟𝑎𝑐𝑡𝑖𝑜𝑛





3.2.7 Statistical Analysis 
Statistical analysis was performed by JMP Pro 12 software. Response surface 
analysis was used to generate the prediction profiles of OPN and total protein adsorption 
to mixed-modal sorbents in response to pH and NaCl concentration. One-way ANOVA in 
JMP Pro was used on data from batch adsorption experiments to test the effects of resin 
types on OPN recoveries and purification factors. After confirming that resin types led to 
significantly different purification outcomes, a Tukey-Kramer HSD analysis was 
performed at α = 0.05 level to compare between resins [178, 179]. 
3.3 Results and Discussion 
3.3.1 OPN Adsorption Studies 
The acidic and hydrophobic nature of OPN prompted us to test mixed-modal resins 
with anion exchange and hydrophobic interaction capabilities. HEA HyperCel, PPA 
HyperCel and Capto adhere resins are commercially available resins having both anionic 
and hydrophobic properties. Plate-based HTS was used to study the interaction between 
proteins and ligands under varying conditions to design bind and elute processes for OPN 
purification. Batch adsorption experiments were used as a rapid scale-down platform for 
resin performance evaluation. 
3.3.1.1 HEA HyperCel Adsorption Studies 
HEA HyperCel has a cellulose-based matrix with hexylamine ligand (Table 3.1). 
This ligand has anionic (pKa ~ 8) and hydrophobic properties at neutral pH, which should 




To investigate the interaction between OPN and the HEA ligand, HTS experiments 
were conducted in the pH range from 5 to 9 and salt concentrations from 0 to 3 M NaCl. 
The unbound OPN and total protein (TP) after equilibrium adsorption were quantified by 
ELISA and Bradford assay respectively [176]. Response surface analysis and the 
prediction profiles of OPN and TP bound to HEA resin are shown as Figure 3.1. 
The contour profile of OPN adsorption (Figure 3.1a) shows that at any particular 
salt concentration within the tested range, OPN adsorption increased in pH 5 to 9 range. 
Salt concentrations of highest interest relevant to OPN capture are the two areas in contour 
plot where OPN adsorption was greater than 80%. These include the segments around pH 
7 and salt concentrations below 0.3 M and above 2.7 M, respectively. In the lower 
concentration salt range (0 - 0.3 M) the majority of OPN was apparently adsorbed 
primarily by electrostatic interactions and as the salt concentration increased to 1 M NaCl 
these interactions were substantially weakened resulting in reduced OPN adsorption by as 
much as 50%. In the high-salt range (NaCl concentrations > 2.7 M) where hydrophobic 
interactions are expected to dominate, the adsorbed OPN fraction at pH 7 increased back 
to 80-90% level. The impact of pH and NaCl concentration on total protein (Figure 3.1b) 
was minimal as the most of host cell proteins were bound at greater than 80% level across 
the pH range. The latter outcome was not unexpected since the proteome of E. coli consists 
of array of proteins with a wide-range of charge and hydrophobic properties. The general 
observation is that a higher NaCl concentration led to a greater amount of protein 





Figure 3.1 Contour profile of OPN (a) and total protein (b) bound to HEA HyperCel. 
Numbers on the contour grids represent the fraction of protein in the lysate that was 
adsorbed to HEA HyperCel 
 
Per HTS results high-salt (3 M NaCl) and low-salt (0.15 M NaCl) adsorption 
conditions were selected for further investigation. For the batch adsorption under low salt 
condition, the clarified cell lysate was incubated directly with HEA resin for 1 hour at 
room temperature as described in Materials and Methods section. No resin conditioning 
was required as HTS results in Figure 3.1a predicted more than 90% of OPN would be 
bound at 150 mM NaCl, 50 mM Tris pH 7. 
Based on the screening results in Figure 3.1, we designed a 3-step elution process 
for complete desorption of OPN using a combination of pH and salt concentration changes 
that gradually weakened hydrophobic and charge interactions and eventually led to 
electrostatic repulsion. The elution steps consisted of 1 M NaCl, 50 mM Tris buffer at pH 




without NaCl addition. The recovery of OPN and total soluble protein from the initial 
loading sample in each step are shown in Figure 3.2a. 
As predicted by HTS data at pH 7, a very small amount of OPN (5%) was detected 
in the flowthrough fraction, whereas more than 40% of E. coli total protein did not bind 
to HEA and remained in the flowthrough. After resin washing with the binding buffer, 
NaCl concentration was increased to 1 M for the first elution step while keeping the pH at 
7. Because the majority of bound OPN (76%) but only 6% of the bound E. coli protein 
was desorbed under those conditions, this step alone resulted in 14-fold purification of 
OPN. The rest of the adsorbed OPN was recovered in the subsequent elution steps. 
 
 
Figure 3.2 Batch adsorption and elution of OPN and E. coli total proteins using HEA 
HyperCel. (a) Low-salt adsorption: adsorption was performed from E. coli clarified 
lysate containing 150 mM NaCl at pH 7. (b) High-salt adsorption: Adsorption was 
performed from conditioned E. coli clarified lysate with 3 M NaCl in 50 mM Tris, pH7. 
Elution steps following for both adsorption conditions: 1 M NaCl, 50 mM Tris, pH 7; 1 
M NaCl, 0.1 M sodium acetate, pH 5; 0.1 M sodium citrate pH 3 with no NaCl. 
 
For adsorption experiments at high-salt, the resin was equilibrated with the binding 




NaCl concentration before incubation. The same elution steps and conditions as in the low 
salt adsorption experiments were applied (Figure 3.2b). 
Under high salt conditions, hydrophobic interactions were apparently the 
dominating factor. More than 80% of E. coli proteins and 92% OPN were bound to HEA 
resin. After resin wash with 10 CV of binding buffer, the first elution step was done with 
1 M NaCl in 50 mM Tris pH 7. The majority of OPN (74%) and 10% of total protein were 
desorbed in the first elution step achieving 7-fold purification of OPN in a single step. The 
rest of the bound OPN was recovered in the two subsequent elution steps (Figure 3.2b). 
3.3.1.2 PPA HyperCel Adsorption Studies 
PPA HyperCel is another mixed-modal adsorbent with phenylpropylamine ligand 
(Table 3.1). The same set of HTS experiments was performed with PPA as previously 
with the HEA HyperCel resin. The prediction contour profile of OPN amount adsorbed to 
the PPA HyperCel is shown in Figure 3.3a.  
The adsorption behavior of total protein with PPA HyperCel (Figure 3.3b) was 
similar to HEA HyperCel resin reflecting the similarity of ligand structures. However, 
PPA HyperCel adsorbed the majority (>90%) of OPN over the whole range of pH and salt 
conditions. This different OPN adsorption outcome indicates that the aromatic ring in the 





Figure 3.3 Contour profile of the proportion of OPN (a) and total protein (b) bound to 
PPA HyperCel. Numbers on the contour grids represent the fraction of protein in the 
lysate that was adsorbed to PPA HyperCel 
 
The elution of adsorbed proteins from PPA resins was tested using the same pH 
and salt conditions as with HEA. As predicted by HTS, the E. coli proteins behaved 
similarly on both PPA and HEA HyperCel resins, but the OPN distribution in the eluted 
fractions was different (Figure 3.4a). A small fraction of OPN was recovered in the first 
elution step (1 M NaCl, pH 7) and almost none in the second. The majority of OPN (60%) 
was desorbed from PPA HyperCel at pH 3. Unfortunately, the pH 3 elution fraction also 
contained a significant amount of E. coli host cell proteins, which led to lower purification 
factors (3-fold purification for low-salt binding conditions and 2.5-fold for high salt 
binding). No significant difference in the adsorption and elution profiles of OPN and total 






Figure 3.4 Batch adsorption and elution of OPN and E. coli total proteins using PPA 
HyperCel. (a) Low-salt adsorption: adsorption was performed from E. coli clarified 
lysate containing 150 mM NaCl at pH 7. (b) High-salt adsorption: Adsorption was 
performed from conditioned E. coli clarified lysate with 3 M NaCl in 50 mM Tris, pH7. 
Elution steps following for both adsorption conditions: 1 M NaCl, 50 mM Tris, pH 7; 1 
M NaCl, 0.1 M sodium acetate, pH 5; 0.1 M sodium citrate pH 3 with no NaCl 
 
3.3.1.3 Capto Adhere Adsorption Studies 
Capto adhere is a strong mixed-modal anion exchange resin derivatized with N-
benzyl-n-methyl ethanolamine and designed to bind proteins via electrostatic interaction, 
hydrogen bonding, and hydrophobic interactions. The hydrophobicity of Capto adhere 
ligand is reported to be reduced by the presence of multiple hydroxyl groups (Table 3.1) 
[54]. HTS of OPN and Capto adhere interactions (Figure 3.5) were carried out similarly 
to those for HEA and PPA resin screening. As shown in Figure 3.5, the NaCl concentration 
had a significant impact on OPN and total protein adsorption to Capto adhere. The fraction 
of adsorbed OPN decreased with increasing NaCl concentration, indicating that the 
predominant interactions between OPN and Capto adhere ligands were ionic (Figure 3.5). 
OPN adsorption with Capto adhere in high-salt buffer (3 M NaCl, pH 7) was also tested. 




even in the presence of 3 M NaCl and more than 70% of OPN remained in the flowthrough 
fraction (data not shown). 
Because a low conductivity condition was the only viable option for capturing 
OPN by Capto adhere, batch OPN adsorption experiments were preformed from dialyzed 
lysates (< 4 mS) at pH 7. 
 
 
Figure 3.5 Contour profile of the proportion of OPN (a) and total protein (b) bound to 
Capto adhere. Numbers on the contour grids represent the fraction of protein in the 
lysate bound to the Capto adhere 
 
Batch adsorption experiments were carried out using dialyzed cell lysates (pH 7). 
Preliminary elution data established that stepwise protein desorption with a descending 
pH buffer (0.1 M citrate-phosphate buffer at pH 5, 4 and 3), as suggested by the resin 
vendor, was optimal for the purification of OPN. Around 8% of OPN and 30% of host cell 
protein remained in the flowthrough (Figure 3.6a). After the wash step with the binding 




steps with less than 2% of OPN lost at pH 4. The majority of OPN (78%) was recovered 
in the third elution step when the buffer pH was lowered to 3, a pH below OPN’s pI. 
During this last stage about 17% of E. coli total protein co-eluted with OPN, which 
resulted in 4.6-fold OPN purification. 
 
 
Figure 3.6 Batch adsorption and elution of OPN and E. coli total soluble protein with 
Capto adhere (a) and Capto Q (b). (a) Capto adhere adsorption: E. coli clarified lysate 
was dialyzed to remove salt before adsorption. Binding condition: pH 7, 50 mM Tris 
buffer. Elution steps: 0.1 M citrate-phosphate buffer pH 5, pH 4, and pH 3, respectively. 
(b) Capto Q Adsorption conditions: 50 mM Tris, pH 7 at < 5 mS/cm. Elution steps: 50 
mM Tris, pH 7 containing 0.2 M, 0.5 M, and 1 M NaCl, respectively 
 
3.3.1.4 Anion Exchange (Capto Q) Adsorption Studies 
The strong anion exchange resin Capto Q was tested with the same batch 
adsorption protocols as the mixed-modal resins. Our preliminary adsorption data using 
clarified E. coli lysates indicated that OPN binds efficiently in the pH range between 6 
and 8. However, significantly more E. coli total proteins were bound to Capto Q at pH 8 
than at pH 6 and 7. Because pH 7 was the optimal condition of OPN extraction, protein 




adsorbed OPN effectively under those conditions. Following the washing step with 
binding buffer, OPN was eluted stepwise from the resin using 0.2 M, 0.5 M, and 1 M NaCl 
solution buffered by 50 mM Tris at pH 7. The relative total protein (TP) and OPN amounts 
in each fraction are plotted in Figure 3.6b. The flowthrough contained 31% of total protein 
and less than 5% of OPN. The first elution step (0.2 M NaCl) removed the bulk of adsorbed 
E. coli total protein (44% of the total protein in the feed) with about 2% loss of OPN. The 
second elution step eluted almost all of the bound OPN (92%) and residual E. coli proteins 
(16%). The elution process resulted in a six-fold increase in OPN purity (from 4% to 23%) 
and 92% OPN recovery. 
3.3.2 Resin Performance Evaluation and Comparison 
All the batch adsorption experiments were conducted in triplicate with similar 
loading volumes and total protein concentration (30 mg TP/mL resin). The binding and 
eluting conditions, purification factors, and OPN recoveries are summarized in Table 3.2 
and are based on a single OPN elution fraction with the highest OPN recovery and not 
necessarily in the highest purification factor. OPN recoveries from the resins did not 
significantly differ because bind/elute process in batch adsorption experiments were 
designed to maximize OPN recovery in a single elution fraction. The resins in the 
summary table were ranked by the purification factors achieved. 
One-way ANOVA test on the effect of resin type on OPN purification factor 
resulted in a P-value less than 0.0001, indicating that tested resins and conditions produced 
significantly different purification outcomes. Tukey-Kramer HSD analysis indicated that 




significantly higher than the rest of the candidate resin ( = 0.05). Besides the highest 
purification factor, HEA HyperCel also demonstrated a salt-tolerant protein adsorption, 
which allowed the direct capture of OPN from the cell lysate without additional 
conditioning step normally required by traditional ion exchange and hydrophobic 
interaction resins. The salt-tolerant adsorption feature of HEA HyperCel is important 
because a diafiltration or titration on crude lysate on a manufacturing scale would 
significantly increase processing time and potentially cause degradation. Despite the 
similarities to HEA HyperCel resin, PPA HyperCel and Capto adhere did not perform as 
well for OPN purification. The aromatic ring structure on the PPA ligand provided strong 
hydrophobic interaction capability with proteins which turned out not ideal for OPN 
purification. PPA HyperCel not only required multiple elution steps to recover OPN but 
did not achieve the separation HEA HyperCel did. Capto adhere, on the other hand, failed 
to provide the hydrophobic interaction needed for OPN capture and performed similar to 





Table 3.2 A summary of OPN bind/elute conditions and respective purification factors 
and recoveries. Recoveries and purification factors are expressed as mean ± standard 
deviation 
 
3.3.3 Verification of HEA HyperCel Performance in a Packed-Bed Column  
To confirm the validity of HEA resin performance, the batch adsorption and 
elution process was repeated in a packed-bed configuration (1 mL prepacked PRC HEA 
HyperCel) using the same feed composition and load volume. The ÄKTA system allowed 
us to investigate if additional purification of OPN could be achieved by using a linear 
gradient instead of stepwise elution. The A280 trace, conductivity expressed as NaCl 
concentration, and OPN concentration in the collected fractions determined by ELISA are 




the A280 curve, which reached its peak at 1 M NaCl. Fractions (36-50 mL) spanning the 
concentration gradient from 0.6 M to 1.1 M NaCl contained 97% of loaded OPN, which 
(as expected) was substantially greater than the 76.4 % observed from the equilibrium 
batch adsorption. The gradient elution of OPN from packed-bed HEA column resulted in 
16-fold purification, a slightly higher value than 14-fold achieved by the 1 M NaCl step 
(Figure 3.2a). This discrepancy can be ascribed to the loosely packed resin and the gravity 
driven flow, which resulted in a varying flowrate and probably some axial dispersion due 
to back mixing. 
The attempt to translate OPN adsorption to HEA HyperCel in high-salt (3M NaCl) 
conditions using packed-bed column resulted in a significant pressure build-up during 
simple loading. In spite of the DNase treatment and clarification of the conditioned lysate 
by centrifugation and filtration prior to loading, the pressure exceeded the resin’s 
maximum pressure resistance of 0.3 MPa during the sample loading at 60 cm/h (0.2 
mL/min). After two attempts with newly packed-bed resin, we concluded that the pressure 
build-up was caused by protein precipitation on the column and decided to not proceed 
with the development of OPN purification under high-salt (3 M NaCl) binding conditions. 
In spite of observed variability, we demonstrated that batch adsorption and elution 






Figure 3.7 Chromatogram of HEA HyperCel low salt bind/elute operated by ÄKTA 
system. Clarified lysate was loaded onto the equilibrated PRC HEA HyperCel column (1 
mL) at 0.2 mL/min to ensure 5 minutes residence time. The column was washed with 20 
CV of binding buffer and eluted by linear NaCl gradient (0.15 to 1.5 M NaCl over 20 
CV). OPN eluted in the peak around 1 M NaCl illustrated between the vertical dark 
broken lines. This experiment was duplicated and yielded reproducible results 
 
3.3.4 Two-Step Purification of OPN by HEA and Capto Q Chromatography 
The results in Figure 3.7 indicate that OPN should be easily eluted in a single step 
without affecting purification efficiency and yield. The step elution of OPN with 50 mM 





Figure 3.8 The chromatogram of OPN step elution from HEA HyperCel. Clarified 
lysate was loaded onto the equilibrated PRC HEA HyperCel column (1 mL) at 0.2 
mL/min. The column was washed by 20CV binding buffer. Elution was achieved by 50 
mM Tris buffer, pH 7, 1 M NaCl. The process was repeated twice and yielded 
reproducible results 
 
The main motivation for choosing a step elution over gradient elution was to obtain 
a higher-protein concentration pool and reduce elution buffer volume, the latter being 
important at a manufacturing scale (Figure 3.8). The eluted OPN pool was loaded to 
HiTrap Capto Q column (1 mL) after salt removal by dialysis. A linear salt gradient (0-
1.0 M NaCl) was used to achieve additional separation of OPN from E. coli proteins.  The 
bound protein eluted in 3 major peaks (Figure 3.9), and OPN was recovered in the second 





Figure 3.9 Chromatogram of OPN purification on Capto Q following the HEA 
HyperCel capture step. The eluted OPN pool was loaded to HiTrap Capto Q column (1 
mL) at 0.2 mL/min flowrate after salt removal by dialysis. Linear ascending salt gradient 
(0-1.0 M NaCl) was used to further purify OPN from E. coli proteins. OPN eluted in the 
peak illustrated between the vertical dark broken lines (32.3 to 33.8 mL). The process 
was repeated twice and yielded reproducible results 
 
The data of OPN purification process by HEA and Capto Q chromatography are 
summarized in Table 3.3 and Figure 3.10. The capture step by HEA HyperCel elevated 
OPN purity from 2% in the crude lysate to 29% resulting in a 15.6 purification factor. This 
step yielded 81% OPN recovery measured by ELISA. The subsequent dialysis of the OPN 
pool aimed at reducing the ionic strength to less than 5 mS/cm for optimal adsorption to 
Capto Q resin resulted in 61% OPN yield. The dialysis step, which was repeated several 
times with step-eluted OPN pools, resulted in 39 - 44% loss of OPN presumably due to 
OPN binding to the dialysis membrane. The latter assumption is based on the observation 




experiments (Figure 3.6b) did not result in a measurable OPN losses. Because no OPN 
was detected by ELISA in the dialysis buffer, we believe that low OPN concentration (67 
µg/mL) in the pool of 233 µg/mL total protein was the reason for higher than expected 
OPN loss due to adsorption to the dialysis membrane. We expect this loss can be reduced 
once the process is scaled up, which would allow the use of tangential flow diafiltration. 
The shear force and higher membrane processing capacity enabled by tangential flow 
filtration on a large pool would help reduce protein adsorption to the membrane. By 
experimenting with key process parameters such as shear rate, protein concentration, and 
transmembrane pressure, an optimized tangential flow diafiltration process is expected to 
achieve higher yield during buffer exchange. 
The second purification step, Capto Q packed-bed column, provided the necessary 
orthogonality to HEA and delivered additional 3-fold OPN purification at 90% recovery. 
Overall, the two-step purification process resulted in 44% OPN yield and 95% purity 
(Figure 3.10). The integration of orthogonal methods achieved OPN purification with 
higher purity in fewer unit operations compared to previously reported processes that 





Figure 3.10 Purification of OPN by HEA and Capto Q two-step process. A: SDS-PAGE 
with Coomassie stain (SimpleBlueTM SafeStain); B: Western-blot image. Both images 
are from the identical gel with the same sample loading in each lane. Lane 1: molecular 
weight markers; lane 2: E. coli clarified lysate; lane 3: Partially purified OPN fraction 
from HEA HyperCel elute; lane 4: Dialyzed HEA purified fraction as the feed for Capto 
Q chromatography; lane 5: Capto Q pool (fractions 32.3-33.8 mL). For lane 2-5, total 
protein loading was kept constant at 5 µg/lane 
 
 







The comprehensive investigation of three mixed-modal resins with hydrophobic 
and anionic characteristics revealed the effect of subtle ligand chemistries on the 
adsorption strength of OPN and E. coli proteins. The three mixed-modal resins responded 
to variation of pH and salt concentration in a dramatically different fashion. Capto adhere, 
often categorized as a mixed-modal anion exchanger, behaved as a traditional anion 
exchanger and required low conductivity for efficient OPN adsorption. HEA HyperCel 
proved to be mixed-modal resin with seemingly an optimal combination of hydrophobic 
interaction and anion exchanger properties for OPN purification. Protein adsorption 
occurred at both low-salt and high-salt concentration conditions. The hydrophobic arm of 
the ligand apparently helped achieving a salt-tolerant adsorption of OPN i.e. binding in 
the presence of 0.15 M NaCl. Interestingly, when the salt concentration in the adsorption 
buffer was greater than 2.7 M NaCl, the hydrophobic interactions became the dominating 
mechanism that resulted in greater adsorption of OPN. However, high-salt binding 
conditions were not conducive to OPN capture from clarified lysates using a packed-bed 
column because of pressure buildup. PPA HyperCel resin, a close sibling of HEA 
HyperCel, performed less efficiently as the aromatic ring on PPA ligand turned out to be 
too hydrophobic and OPN could not be easily eluted from PPA. 
Different interaction chemistries of HEA HyperCel and Capto Q allowed the 
development of an orthogonal purification of OPN. The two-step process consisting of 
HEA followed by Capto Q achieved increase in OPN purity from 2% in the lysate to 95% 




and is achieved with fewer steps. The overall yield can be further improved when the 
process is optimized on a larger scale. The process described in this study took advantage 
of the salt-tolerant property of mixed-modal resin HEA HyperCel, which eliminated the 
need for dialysis/diafiltration of E. coli lysate before the capture chromatography step. 






HIGH-THROUGHPUT SCREENING OF MIXED-MODE RESINS AND 
INVESTIGATION OF INTERACTION MECHANISM WITH HUMAN 
THIOREDOXIN 
4.1 Introduction 
Protein isolation has traditionally used multiple chromatography operations in 
tandem, each selective to/targeting one property of the protein at a time. A class of 
chromatography resins that interact with multiple facets of the protein chemistry called 
mixed-mode resins is rapidly expanding. Their popularity is due to the unique selectivity 
that arises from combining interaction chemistries [172]. Enhanced selectivity, achieves 
the desired purification with reduced number of chromatography operation, avoiding the 
cost and product loss associated with additional unit operations, thereby improving 
process efficiency [23]. Mixed-mode resins provide protein binding in a range of salt-
independent physiological conditions, eliminating the need for pretreatment or 
conditioning [33, 172]. They also have high binding capacity even in the salt-tolerant 
binding conditions [180, 181]. 
Several studies have shown potential for integrating mixed-mode resins as a part 
of the mAb purification platform, either as polishing chromatography or in some cases an 
alternative to Protein A affinity chromatography [24, 50]. The ability to separate mAb 
aggregates or fragments from monomers, improves the process efficiency and is a 
testament to the enhanced selectivity of mixed-mode resins [24, 182, 183]. Diverse 




and bio-polymers, demonstrating their versatile applications [23, 184]. The mechanism of 
interaction between the protein and ligand are complex, with multiple interaction 
mechanisms acting simultaneously often resulting in low protein recovery. To that end, 
additives to the elution buffer called modifiers have been investigated, for targeted 
reduction of each interacting mechanism. Murine antibodies bound to Capto MMC resin 
required a combination of 0.3 M arginine and 0.3 M NaCl in the elution buffer for > 80% 
recovery of mAb [185]. Fundamental understanding of the interaction mechanisms is vital 
for designing optimal adsorption and selective elution to successfully recover the target 
protein [54].  
This study was designed to demonstrate the importance of understanding the 
interaction mechanism involved in adsorption and elution of a recombinant human 
thioredoxin (hTrx) from mixed-mode resins. Human thioredoxin-1, is a small 12 kDa 
protein, ubiquitous to all organisms. It has a redox active site responsible for maintaining 
a reduced cellular environment. hTrx has a highly ordered and conserved 4 α-helices, 5 β-
sheet secondary structure resulting in thermal and pH stability. It is an acidic protein with 
a theoretical pI of 4.8 but has low net charge of -6.8 at pH 8, and hydrophathicity index of 
(- 0.096). Currently investigated applications include reducing the mucin network to 
alleviate symptoms of cystic fibrosis. Large dosage of 1.5 to 150 mmol/ kg of patient, 
translating to ~65 g per patient per year, would be needed for administering hTrx by 
aerosol inhalation [186]. Thus, a scalable and high yield process is required to deliver hTrx 




The processes used for purification and scale up of hTrx from E. coli have 
historically been tedious because it lacks distinctive ionic or hydrophobic surface 
properties to allow its efficient capture and purification. In previous reports, purification 
of hTrx starts with a pretreatment step, ammonium sulfate fractional precipitation or heat 
precipitation [133, 136]. The capture chromatography is either hydrophobic interaction 
chromatography or diafiltration followed by ion exchange chromatography. Elution is 
further purified by additional chromatography that are orthogonal and require a 
conditioning unit operation like diafiltration, or use the same capture chromatography, 
which is repetitive and decreases the efficiency of separation. Finally, all reported 
processes invariably use size-exclusion chromatography to obtain a purified 12 kDa hTrx 
[132, 133, 136]. The recovery of such a multi-chromatography operation is 40 - 50%. The 
enhanced selectivity offered by mixed-mode resins could be beneficial in improving the 
downstream processing efficiency of hTrx. 
In this study, custom Prometic ligand library and commercial mixed-mode resins: 
Capto adhere, HEA HyperCel, Toyopearl NH2-750F were tested. The total protein and 
hTrx binding were screened using high-throughput screening on a 96-well filter plate. The 
chromatography resin that showed most potential was selected for the capture of human 
thioredoxin directly from the E. coli cell lysate. The mechanism of interaction was studied 
by experimentally varying the binding and elution conditions. Several elution buffer 
modifiers were tested to disrupt the protein-ligand interactions and target specific modes 




mechanism between hTrx and mixed-mode ligand, molecular dynamics simulations using 
Desmond Schrödinger was employed.  
The objectives of this study were to- 
1. Demonstrate the versatility and separation efficiency of mixed-mode resins 
compared to single-mode reins 
2. Explore the available interaction mechanisms on the mixed-mode resin 
experimentally and by molecular modelling 
3. Optimize the binding and elution conditions by high-throughput screening to 
maximize thioredoxin recovery and purity 
4.2 Materials and Methods 
4.2.1 Recombinant Strain and Biomass 
Recombinant E. coli BL-21 with a human thioredoxin-1 (accession number 
P10599) insert was provided by OrPro Therapeutics, Inc., California. Protein expression 
was controlled by a rhamnose inducible promoter and kanamycin selective marker.  
E. coli cells were grown in LB media in a 4L New Brunswick bioreactor at 
National Center for Therapeutics Manufacturing, Texas A&M University. Cells were 
grown at 37°C for 5 h, then induced with 5 mM rhamnose at 32°C for 6 h, with pH and 
dissolved oxygen set at 7.0 and 40% respectively. The biomass accumulated was harvested 






4.2.2 Lysate Preparation  
Cells lysis was performed at 1g biomass in 10 mL buffer ratio. Cells were disrupted 
by sonication (QSonica, US) on ice at 40% amplitude, 30s on/off cycle for 5 min. The cell 
debris was removed by centrifugation at 10,000xg for 30 min at 4°C and the supernatant 
was sterile filtered to prepare the clarified lysate.  
4.2.3 Lysis Buffer Optimization 
The buffer pH and conductivity for cell lysis was optimized based on maximum 
hTrx recovery and starting purity. Triplicates of clarified lysate were prepared in different 
lysis buffer conditions (50 mM sodium citrate, 5 mM DTT pH 3.0; 50 mM sodium acetate, 
5 mM DTT pH 5.0 and 50 mM Tris, 5 mM DTT pH 7.0) each with and without 500 mM 
NaCl. The optimized lysis buffer was then used to prepare the clarified lysate, which was 
the starting material for the rest of the experiments. 
4.2.4 Selection of Capture Chromatography  
Single-mode (Capto Q, Phenyl sepharose) and mixed-mode resins (Prometic 
ligand library, Capto adhere, HEA HyperCel, Toyopearl NH2-750F) were purchased or 
donated from the manufacturers (Table 4.1). To select the ideal resin for capture 
chromatography, hTrx and host cell protein (HCP) binding were tested at different pH and 
conductivity (2 to 10 mS) conditions, using a high-throughput screening in a 96-well filter 
plate (Empore, 3M, US). Each well contained 50 µL of resin volume (CV) equilibrated to 
respective binding pH and conductivity, and incubated with 250 µL (5 CV) of clarified 




performed in triplicate. Incubation was performed for 30 min by vortexing at room 
temperature. The filtrates from each well, that will be referred to as flow through were 
collected by centrifugation at 3000xg for 2 min or by applying vacuum. The collected flow 
through samples were analyzed for hTrx by ELISA and HCP by Bradford assay. To 
compare the adsorption preference of individual resins for hTrx relative to HCP, a relative 
binding ratio (k) defined as the ratio of % bound hTrx to % bound HCP was calculated for 
each pair of tested (pH and conductivity) conditions. 
4.2.5 Optimization of Elution Conditions 
The best performing resin and binding conditions was selected for elution 
optimization. Elution buffers 10 CV were tested by high-throughput screening on a 96-
well filter plate as described above. Buffers containing arginine HCl, guanidine HCl and 
lysine HCl were also screened at varying concentrations of 0.1 – 0.5 M. The optimal 
elution buffer was selected based on maximum hTrx recovery and purity of the elution 
fraction. 
4.2.6 Packed-Bed Chromatography 
Twenty mL of the clarified lysate at optimized binding condition was loaded on 1 
mL HEA PRC column attached to ÄKTA Purifier 10 at 0.25 mL/min. The column was 
washed with 10 CV of lysis at 0.5 mL/min. Bound proteins were eluted with a gradient of 
optimized elution buffer over 20 CV at 0.5 mL/min. Two mL fractions were collected and 
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4.2.7 Analytical Techniques 
The performance of chromatography resins were evaluated based of % protein 
recovery and % purity calculated as follows. 
𝑃𝑒𝑟𝑐𝑒𝑛𝑡 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 𝑟𝑒𝑐𝑜𝑣𝑒𝑟𝑦 (𝑜𝑟) 𝑦𝑖𝑒𝑙𝑑 =
(𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 𝑎𝑓𝑡𝑒𝑟 𝑢𝑛𝑖𝑡 𝑜𝑝𝑒𝑟𝑎𝑡𝑖𝑜𝑛)
(𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 𝑏𝑒𝑓𝑜𝑟𝑒 𝑢𝑛𝑖𝑡 𝑜𝑝𝑒𝑟𝑎𝑡𝑖𝑜𝑛)




(𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑝𝑟𝑜𝑑𝑢𝑐𝑡 + 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 𝑖𝑚𝑝𝑢𝑟𝑖𝑡𝑖𝑒𝑠)
 * 100 
 
𝑃𝑢𝑟𝑖𝑓𝑖𝑐𝑎𝑡𝑖𝑜𝑛 𝑓𝑜𝑙𝑑 =




HCP concentration measurements were calculated using Bradford assay (Thermo 
Fisher Scientific, USA) on a microtiter plate format with BSA as standard [176]. The 
absorption was measured at 595 nm using VERSA Max microplate reader. 
hTrx concentrations were measured by indirect ELISA. Protein samples were 
immobilized on a Nunc maxisorb plate and incubated with anti-thioredoxin monoclonal 
antibody (Abcam, USA) at 1:7500 dilution followed by anti-mouse polyclonal HRP at 
1:10,000 dilution (Sigma, USA). The reaction was developed using TMB developer 
(Sigma, US) and stopped with 1 M HCl, absorbance at 450 nm was measured using 
VERSA Max plate reader.  
Reducing/Denatured SDS-PAGE was used to visualize the protein makeup in a 
sample. Eight to twelve µg/well of denatured protein samples were loaded on NuPAGE 
Novex 4 - 12% Bis-Tris pre-cast gradient gels (Thermo Fisher Scientific, USA) and 




SimplyBlue SafeStain Coomassie G-250 stain (Thermo Fisher Scientific, USA) and 
analyzed against a SeeBlue Plus2 pre-stained protein standard (Thermo Fisher Scientific, 
USA). ImageJ v.1.49 software was used to calculate purity of proteins in each sample lane 
[177].  
The size of hTrx was analyzed using TSK gel 2000 SWxL column (Tosoh, USA) 
connected to ÄKTA purifier 10 equipped with a fraction collector. Thirty microliters (30 
µL) of concentrated sample (containing at least 1 mg/mL protein) was injected on the 
column and run at 1 mL/min for 15 min in 100 mM sodium phosphate, 5 mM DTT, pH 
7.0.  
Activity of hTrx was determined at pH 7 using a previously described method of 
insulin precipitation by thioredoxin [188]. Briefly, hTrx reduces the interchain disulfide 
bonds in insulin molecule resulting in precipitation which is monitored by the change in 
absorbance at 650 nm.  
4.2.8 Statistical Analysis 
All high-throughput screening experiments were conducted in triplicates. JMP Pro 
12 software was used to for statistical analysis. Analysis of variance was performed and 
triplicates of the treatments were compared for significant difference using Tukey-Kramer 
HSD test at α = 0.05. 
4.2.9 Molecular Dynamics 
Desmond Schrödinger software suite was used to perform the molecular modelling 




process is briefly described schematically in Figure 4.1. PDB file (1ERT) of hTrx from 
X-ray crystallography was obtained and pre-processed to include polar hydrogens atoms 
and minimize molecular energy. The hexylamine (HEA) ligand was created using Maestro 
and 12 molecules of HEA were distributed randomly around 1 protein, to replicate the 
experimental ratio. All proteins, ligands and additives were protonated corresponding to 
pH 5.0 + 0.2 to emulate the experimental conditions. A solvation box of 55, 50, 50 Å size 
was created with water and neutralized with sodium chloride ions according to the TIP4P 
model [189]. Molecular dynamics was performed for 1.2 ns to relax the system and impart 
random starting orientations. Six frames of this run were used as starting points for 
molecular dynamics simulation, each for 40ns. These runs were under NPT conditions, 
for constant pressure under Optimized Potentials for Liquid Simulations (OPLS) force 
field. These were merged for a total trajectory of 240 ns and analyzed for interaction 
energies (Appendix Figure A4). Chimera was used to create the visual representations. 
The simulations were repeated with a dimer of hTrx (1ERT), in its oxidized form with a 
solvation box of 75, 55, 85 Å size. 
 
 
Figure 4.1 Detailed schematic of the steps involved in molecular modelling of hTrx 





4.3 Results  
4.3.1 Lysis Buffer Optimization 
The first step in downstream process development is cell lysis. Starting off with 
the most hTrx recovery and higher purity is paramount to an efficient purification process. 
Varying buffer pH (7, 5, and 3) for cell lysis were tested. pH 7 and 3 were tested for being 
2 points over and below the pI of the protein. pH 5 was tested because it was close to the 
pI of hTrx (4.8) but also close to the pI of other acidic protein impurities from E. coli cell. 
The impact of 500 mM NaCl to release any proteins bound electrostatically to the cell 
debris was also tested. The hTrx recovery and purity were measured by Bradford and 
ELISA assays and shown in Figure 4.2. 
 
 
Figure 4.2 Impact of lysis buffer conditions of cell lysis. Error bars indicate standard 





Cell lysis at pH 3, resulted in poor recovery of hTrx. Since the addition of salt does 
not recover more than 45% of the hTrx, the reduced extractability is probably not due to 
electrostatic interaction with the cell debris. By crossing the isoelectric point to reach pH 
3, hTrx solubility is affected, resulting in a lower extractability. Compared to pH 7, cell 
lysis at pH 5 released all of hTrx from the cell (95.4% recovery). The HCP content, 
however, was reduced significantly (2-fold) at pH 5, leading to an increase in hTrx purity 
by 1.9 fold. The differential solubility of hTrx and HCP at pH 5, despite being close to its 
pI, can be attributed to the highly ordered secondary structure of hTrx. The presence of 
NaCl in the lysis buffer did not have an effect on the hTrx recovery or on increasing lysate 
purity, and thus, was not included in the lysis buffer. The optimized lysis buffer consisted 
of 50 mM sodium acetate, 5 mM DTT at pH 5. DTT was present in all buffers used in this 
study to ensure reduced state of hTrx dithiols groups.  
4.3.2 High-Throughput Resin Screening for Capture Chromatography 
4.3.2.1 Single-Mode Resins 
Equilibrium hTrx binding to traditional ion exchange resin, Capto Q, was tested at 
pH above the pI of the protein (pH 5, 7 and 9) to prevent hTrx precipitation and at varying 
conductivities (2, 5 and 10mS) by high throughput screening and the percent hTrx in flow 
through was analyzed (Figure 4.3a). Interaction between hTrx and Capto Q at lysate pH 
of 5, was poor. Since the binding pH is close to the pI of hTrx, the overall charge of the 
protein was insufficient for strong electrostatic interactions with the quaternary amine 




bind hTrx. As the conductivity increases beyond 2 mS, the binding of hTrx is deterred 
substantially. Increasing the binding pH to 7 or 9, improved hTrx binding, due to increase 
in the net negative surface charge of hTrx. However, at these conditions (pH 7 or 9), the 
HCPs were also more negatively charged, resulting in more bound HCP (Figure 4.3b) and 
lower adsorption selectivity. Due to the small size and low surface charge of the protein, 
hTrx binding to Capto Q resin was highly sensitive to the conductivity.  
 
Figure 4.3 High throughput screening of (a) percent hTrx and (b) HCP in Capto Q resin 
flow through across pH 5, 7 and 9 over 2 to 10 mS conductivity 
 
Hydrophobic interaction chromatography of hTrx with Phenyl Sepharose resin 
was also tested by high-throughput screening at pH 5, 7 and 9 and ammonium sulfate 
concentration ranging from 1 to 3 M (Figure 4.4). Data in Figure 4.4 indicate that high 
concentrations of ammonium sulfate (>2 M) would be required for complete binding of 
hTrx to the chromatography resin irrespective of the binding pH. Despite the high salt, the 
binding to the resin was weak, and hTrx was lost in the washes, further 30% loss of hTrx 




not favorable as they increase the buffer viscosity and promote protein aggregation, hTrx 
aggregates have decreased activity and should be avoided [190].  
 
 
Figure 4.4 High throughput screening of percent hTrx in Phenyl Sepharose resin 
flowthrough across pH 5, 7 and 9 over 1 to 3 M ammonium sulfate concentrations 
 
In conclusion, the two commonly used single-mode chromatography resins would 
not be optimal for direct capture of hTrx from clarified lysates, and search for alternative 
adsorption resins with different chemistries seems warranted.  
4.3.2.2 Mixed-Mode Resins 
Prometic Ligand Library 
Ninety six different ligands were provided in a microtiter filter plate by Prometic 
ligand library. Each well was a unique combination of ligands connected by a triazine 




pH 5 and 2 mS was loaded to zone 1 (anion exchanger), zone 2 and 4 (corresponding to 
anion exchange with aliphatic and aromatic hydrophobic ligands respectively). The flow 
through was analyzed for HCP and hTrx and the 8 best performing resins were selected 
for further evaluation (data not shown). These 8 resins, were tested for salt-tolerant 
binding at conductivity of 2, 5 and 10 mS, and pH 7 or 8. The relative binding ratio (k) 
was calculated by the ratio of % hTrx bound to the % HCP bound under each condition. 
Among the resins that displayed hTrx binding at moderate salt concentrations, the two 
resins that had the highest relative binding ratio, were D1 and D8. Resin D1 was a general 
ion-exchanger (zone 1), which has k = 2.8 at the optimized pH of 8.0 (Table 4.2). Resin 
D8 (zone 4) was a mixed-mode resin, which bound 91% of hTrx with relative binding 
ratio of 1.6 at the optimized pH of 8.0. D1 and D8 resins provided in bulk by Prometic 
Bioseparations were further evaluated by batch chromatography.  
 
 





Table 4.2 Relative binding ratio (k) for top 8 resin candidates at optimal binding pH and 






 2mS 5mS 10mS 
B1 7 1.5 0.9 0.7 
C1 8 1.7 0.6 - 
D1 8 2.8 1.3 0.5 
D2 8 1.5 1 0.3 
D5 8 1.6 1 - 
A7 8 2 - - 
D8 8 1.6 1.3 0.7 
D9 8 1.8 1.3 0.8 
 
Commercial Mixed-Mode Resins 
Mixed-mode resins were tested in triplicates for equilibrium hTrx binding at pH 6, 
7 and 8 and conductivities ranging from 2 to 10 mS (Figure 4.6). Toyopearl NH2-750F 
showed poor binding of hTrx throughout the binding conditions screened. Even at higher 
pH of 8, where hTrx has a relatively high negative net charge, and 2 mS conductivity, 80% 
of hTrx remained unbound in the flowthrough resulting in low relative binding ratio (k) 
of 0.4 (Table 4.3). Capto adhere bound hTrx in low to moderate conductivity range 
between 2 and 5 mS. Despite minimal net charge on the protein at pH 6, relative binding 
ratio of k=1.6 at 2 mS was achieved. At pH 7 and 8, where hTrx is negatively charged, 
complete protein adsorption occurred at moderate conductivities of 7.5 and 10 mS, 
respectively (Figure 4.6b). In spite of the relatively high k values ranging from 1.2 to 1.6 
(Table 4.3), it should be noted that hTrx interaction with the Capto adhere was sensitive 
to conductivity. An extrapolation from the contour plot (Figure 4.6b) shows 20% of hTrx 




function of ionic strength, indicates a decrease in the adsorption strength due to weaker 
charge interactions, albeit the binding was moderately salt-tolerant.  
 
 
Figure 4.6 High throughput screening of percent hTrx in flowthrough of (a) Toyopearl 
NH2 750F (b) Capto adhere and (c) HEA HyperCel mixed mode resins across pH 6, 7 





Table 4.3 Relative binding ratio (k) for mixed-mode resins Toyopearl NH2 750F, Capto 
adhere and HEA HyperCel across pH 6, 7 and 8 over 2 to 10 mS conductivities. Average 
of triplicate measurements are shown 
 
HEA HyperCel resin also displayed salt-tolerant binding with hTrx, across pH 6 
to 8, consistently with k value ranging from 1.2 to 1.4 across all the screened binding 
conditions. At pH 7 and 8, complete binding of hTrx is observed (Figure 4.6c), even at 10 
mS. At the pH 6, hTrx still binds completely to HEA HyperCel at 6.5 mS, when compared 
to Capto adhere which had a predicted 20% hTrx in the flow through under the same 
conditions (Figure 4.6). Similar to Capto adhere, hTrx binding to HEA HyperCel was 
gradually weakened by increase in conductivity, reflected in the decrease in relative 
binding ratio (Table 4.3), indicating that electrostatic interactions are playing a role in the 
protein adsorption to HEA.  
Capto adhere and HEA HyperCel along with chromatography resins D1 and D8 
from Prometic ligand library were further evaluated by batch chromatography experiments 
to determine their recovery and purification potential.  
  
 
Toyopearl NH2 750F Capto adhere HEA HyperCel 
 
2 mS 5 mS 10 mS 2 mS 5 mS 10 mS 2 mS 5 mS 10 mS 
pH 6 0.3 0.0 0.0 1.6 1.2 0.8 1.4 1.3 1.2 
pH 7 0.0 0.2 0.0 1.6 1.3 1.2 1.4 1.3 1.3 




4.3.3 Testing the Recovery and Purity of Selected Mixed-Mode Resin Candidates  
Batch chromatography was performed on 0.5 mL gravity flow columns, with direct 
loading at the clarified lysate conditions (pH 5, 5 mS) and adsorbed proteins were eluted 
stepwise with increasing NaCl concentrations in acetate buffer. Percent purity and 
recovery of hTrx in the elution fractions were determined and listed in Table 4.4. 
The criteria for selecting resins that could be used for capture chromatography 
were set to at least 50% purity and 80% recovery of hTrx to improve on the processes 
reported in the literature. 
Data in the Table 4.4 demonstrate that the Prometic resin D1, a general ion 
exchanger, adsorbed 71.6% of the initial hTrx and released the adsorbed protein at a rather 
low ionic strength (100 mM) elution conditions indicating weak electrostatic interaction 
between the ligand and hTrx. The purity of the eluted hTrx was 33.5%. Resin D8 under 
tested conditions (pH 5, 5 mS) adsorbed only 13.3% of the loaded amount of hTrx. 
Majority of hTrx was lost in the flow through. Neither Prometic chromatography resins 






Table 4.4 Analysis of hTrx purity and recovery from batch chromatography on mixed-
mode resins 
 Prometic ligand 
library resin D1 
Prometic ligand 
library resin D8 



















24.8 100 24.8 100 17.5 100 30.4 100 
Elution 0.1 M 
NaCl 
33.5 71.6 16.8 12.7 42.2 58.2 41.3 16.3 
Elution 0.25 
M NaCl 
0 0 3.4 0.6 25.2 15.6 63.6 9.6 
Elution 0.5 M 
NaCl 
      70 9.7 
Elution 1.0 M 
NaCl 
      86.5 7.6 
Elution 1.5 M 
NaCl 
      71.9 1.9 
Overall 33.5 71.6 10.1 13.3 33.8 73.8 66.6 45.1 
 
GE Healthcare’s Capto adhere resin, completely adsorbed hTrx at the clarified 
lysate conditions of pH 5 and 5 mS. Consistent with the high-throughput screening studies, 
the adsorption strength was low and 58% of adsorbed protein was desorbed with a 
relatively low ionic strength buffer containing 100 mM NaCl (Table 4.4). Although the 




for capture chromatography. The second elution pool of hTrx with 0.25 M NaCl generated 
additional 16% of hTrx at 25% purity. It is possible to select only the hTrx from 100 mM 
NaCl elution to maximize on the purity that can be achieved, but that would be at the 
expense of 16% hTrx from the 250 mM NaCl elution, and such a product loss in the first 
step of protein purification is not ideal. Combined hTrx pools had an average purity and 
recovery of 33.8% and 73.8%, respectively. Similarly to D1, the Capto adhere resin fell 
short of selection criteria threshold. 
HEA HyperCel resin displayed complete hTrx binding at the clarified lysate 
conditions. High ionic strength buffers (> 1 M) desorbed hTrx at an average purity of 67% 
but the recovery of 45% was suboptimal. Although it did not reach the desirable 80% 
recovery benchmark, HEA HyperCel resin was the only mixed-mode resin that displayed 
salt-tolerant binding of hTrx and met the purity criteria. In spite of the suboptimal recovery 
level, HEA HyperCel was selected for further studies for the following reasons- 
1. Binding conditions compatible with direct loading of clarified lysate with minimal 
or no conditioning 
2. Strong adsorption should theoretically allow achieving higher resin loads (and 
greater breakthrough capacity)  
3. Significantly higher purity than other resin candidates provides a wider window of 
opportunity for optimization of desorption conditions (pH, elution buffer additives, 
modifiers, and displacement agents) while maintaining greater than 50% purity.  
The following section addresses the last reason (#3) and investigates elution conditions 




4.3.4 Optimization of Elution Buffer for Improving Recovery of Thioredoxin from 
HEA HyperCel  
To address the suboptimal desorption hTrx, three alternate organic compound-
based elution buffers were explored. The effect of 50 mM Tris, 5 mM DTT, pH 7.0 
containing arginine HCl, guanidine HCl and lysine HCl on hTrx recovery from HEA 
HyperCel resin were tested by high-throughput screening and shown in Figure 4.7a. 
Arginine and guanidine HCl were chosen for their ability to disrupt electrostatic, 
hydrophobic and hydrogen bonding, while lysine HCl for the ability to break electrostatic 
and hydrogen bonding. The highest hTrx recovery of 47% was achieved using 0.25 M 
guanidine-HCl buffer, but it was not significantly (α = 0.05) better than 33% recovery 
with 1 M NaCl containing buffer. Similarly, the hTrx recovery with a 0.25 M arginine or 
0.25 M lysine containing buffer was not significantly different than the other elution 






Figure 4.7 (a) hTrx recovery (%) from HEA HyperCel resin using different elution 
buffers. The effect of 50 mM Tris buffer containing 0.25 M Arginine, Lysine, or 
Guanidine were compared to the same buffer containing 1 M NaCl. Treatments sharing 
the same letter are not significantly different (α = 0.05). Error bars indicate standard 
deviation of triplicate measurements (b) SDS-PAGE of E. coli lysate binding and elution 
profile from HEA HyperCel resin. All samples diluted to <1 mg/mL TSP. Lane 1. MW 
marker, lane 2. Clarified lysate, lane 3. Flow through, lane 4. Washes (3 CV), lane 5. 
Elution with 100 mM NaCl, lane 6. Elution with 1 M NaCl, lane 7. Elution with 250 mM 





Figure 4.7a, demonstrate that each buffer contributes to the desorption of hTrx by 
breaking interactions between the protein and HEA ligand. Previous studies employing 
these buffers demonstrated that arginine and guanidine can affect electrostatic, 
hydrophobic and/or hydrogen-bond interactions, while NaCl disrupts primarily 
electrostatic interaction [35]. The specific desorption mechanism of lysine containing 
buffers has not been widely reported. Based on the molecular structure of lysine, one could 
safely assume interference with the same three types of molecular interactions as arginine.  
The examination of SDS-PAGE eluted protein profiles (Figure 4.7b) shows that 
arginine elution buffer desorbed different host cell proteins than NaCl (Figure 4.7b lanes 
6 and 8). These differences, although semi-quantitative in nature, confirm previous reports 
on desorption mechanism and let us hypothesize that the primary desorption mechanism 
of organic compound-based elution buffers and NaCl is different. Therefore, we next 
investigated the potential synergistic effect of combining organic compound-based buffers 
with NaCl buffer, aimed at increasing hTrx elution yield.  
The elution buffers tested consisted of 0.1, 0.25 and 0.5 M arginine HCl, guanidine 
HCl or lysine HCl in 50 mM Tris, 5 mM DTT, pH 7.0 buffer containing 1 M NaCl. The 
data in Figure 4.8, summarize hTrx desorption yields (% recovery) using elution buffers 
that contained NaCl and one of the three organic modifiers. The combined effect salt and 
organic compound-based modifiers on recovery of hTrx from HEA HyperCel resin is 






Figure 4.8 Effect of buffer modifiers on % hTrx recovery in elutions from HEA 
HyperCel chromatography resin. The elution buffers consisted of 0.1, 0.25 and 0.5 M 
arginine HCl, guanidine HCl or lysine HCl in 50 mM Tris, 5 mM DTT, pH 7.0 buffer 
containing 1 M NaCl. The %hTrx recovery values were normalized with the highest 
recovery as 100%. Treatments not sharing the same letter are significantly different (α = 
0.05). Error bars indicate standard deviation of triplicate measurements 
 
0.1 M of arginine, guanidine and lysine HCl combined with 1 M NaCl, efficiently 
eluted hTrx from HEA HyperCel completely (100%). The estimated recoveries were > 
100% possibly due to margin of error in the analytical method to quantify hTrx, therefore 
the highest %hTrx recovery value was normalized to 100% in the figure. The complete 
hTrx recovery was a remarkable improvement compared to less than 50% recovery 
obtained with individual buffers (Figure 4.7), establishing that the combination of each 
buffer modifier at 0.1 M concentration with 1 M NaCl had a synergistic effect on the 
recovery of hTrx. Buffer containing 0.25 and 0.5 M of arginine HCl and guanidine HCl in 




a similar suppression at 0.5 M concentration. The reason for recovery suppression is not 
clear and has not been reported before with any mixed-mode resins. In the absence of 
direct evidence and explanation of the suppression phenomenon, one could speculate that 
the higher concentrations of modifiers in elution buffer promotes rather than disrupts 
protein-ligand interactions similar to the “U-shaped” elution curve reported for some 
mixed mode resins. 
Since any of the three organic modifies (arginine, guanidine, lysine) when 
combined with 1 M NaCl contributes to total hTrx recovery at 0.1 M concentration, we 
have chosen the arginine and NaCl combination to investigate and, if possible, to discern 
their impact on electrostatic, hydrophobic and hydrogen-bond interactions between hTrx 
and the HEA ligand. The main reason for selecting arginine over guanidine or lysine was 
the established body of evidence of using arginine as an elution buffer modifier known to 
preserve protein structural stability of complex therapeutics proteins such as monoclonal 
antibodies [35]. 
4.3.5 Modelling Thioredoxin Interaction with HEA HyperCel 
Molecular modelling studies were performed on hTrx PDB structure (1ERT) to 
simulate interaction with free HEA ligand. The input on binding energies, interaction sites 
and mode of interaction are valuable information about the protein-ligand interaction that 
contribute to knowledge-based experimental design and targeted testing conditions. In this 
case, it was employed to gain an understanding of protein-ligand interaction mechanism 
and supplement experimental findings. Figure 4.9, shows the amino acid sites that interact 




gradient is based on the average interaction strength (kcal/mol) of two modes of 
interaction electrostatic and van der Waals (hydrogen bonding) interaction during the total 
simulation period. Under binding conditions of 0.05 M NaCl, pH 5.0, aspartic acids (16, 
58, 60 and 61) and glutamic acids (13) bind with strong electrostatic energy to HEA ligand, 
the highest being asp 60 with -48.5 kcal/mol. Increasing the NaCl in the system to 1.0 M 
weakens the interactions of these amino acids but aspartic acid 16 and glutamic acids 13, 
95 and 98 are still interacting with the ligand, consistent with the experimental results of 
partial hTrx elution from HEA HyperCel resin. In a system with only arginine of 0.2 M, a 
similar observation, aspartic acid 60 and glutamic acid 70 interact with moderate energies 
of -12.4 and -21.6 kcal/mol. Under the optimized elution condition of elution modifier 
(arginine) in the presence of 1.0 M NaCl, the interactions with ligand are broken with only 
aspartic acid 61 interacting weakly with -14.8 kcal/mol.  
Molecular dynamics also was employed to test the theory that hTrx aggregates are 
retained stronger by the ligand. Dimers of hTrx with 2 intramolecular (cys 32- cys 35) and 
one intermolecular (cys 73- cys 73) disulfide bonds were subjected to the same simulation 






Figure 4.9 Analysis of molecular dynamics showing amino acids in hTrx interacting 
with HEA ligand shaded based on interaction energy (kcal/mol) under (a) 0.05 M NaCl; 
(b) 1.0 M NaCl; (c) 0.2 M arginine; (d) 1.0 M NaCl + 0.2 M arginine conditions 
 
Dimers of hTrx also interact with the HEA ligand with the surface acidic amino 
acids aspartic and glutamic acids. Interestingly, the highest binding energies of dimers, -
37.7 kcal/mol (electrostatic of asp 61.B) was lower than the binding energy of monomer -
48.6 kcal/mol (electrostatic of asp 60). Additionally, phenylalanine 42 and 77 contribute 
to hydrophobic interactions that prevail in high salt conditions as well, but are reversed 
when arginine is introduced. However, the aspartic and glutamic acids still interact with 
the ligand and require the combination of NaCl and arginine to minimize electrostatic 





Table 4.5 Average energies of hTrx amino acids interacting with HEA ligand in the 
























Glu13 -24.7 0.5 Asp26.A -37.1 2.3 
Asp16 -32.0 0.5 Phe42.A -0.7 -3.6 
Asp58 -38.7 1.8 Glu47.B -17.0 0.8 
Asp60 -48.6 1.9 Glu56.A -15.4 0.6 
Asp61 -47.1 2.6 Asp58.A -36.0 0.4 
   
Asp58.B -14.4 0.7 
   
Asp60.A -23.6 1.0 
   
Asp61.B -37.7 1.7 
   
Glu6.A -15.1 -0.6 
   
Glu6.B -25.8 0.5 
   
Phe77.A 0.2 -3.2 
   
Glu95.A -21.8 0.4 
   
Glu95.B -13.8 0.4 
   







Table 4.5 Continued 
Monomer Dimer 



















Asp16 -33.1 0.2 Phe42.A 0.1 -0.5 
Glu95 -23.0 0.6 Asp58.B -21.2 1.2 
Glu98 -19.9 -0.1 Asp60.B -22.3 1.3 
   
Asp61.B -19.0 1.3 
   
Phe77.A -1.0 -3.3 
   
Glu98.B -19.0 0.1 
0.2 M 
ARGININE 
Asp60 -12.5 0.4 Glu13.A -30.5 0.2 
Glu70 -21.4 0.0 Asp16.A -18.2 0.1 
   
Asp58.B -27.8 1.8 
   
Asp60.B -14.4 0.5 
   
Asp61.B -25.4 1.2 
   
Glu98.A -32.8 0.8 
1.0 M NACL 
+ 0.2 M 
ARGININE 






4.3.6 Packed-Bed HEA HyperCel Chromatography  
To simplify the elution process and eliminate the need for pH adjustment after the 
binding of hTrx on the HEA packed-bed column, elution of hTrx using the same binding 
buffer (50 mM sodium acetate buffer, 5 mM DTT at pH 5.0) containing arginine and NaCl 
was tested. The amount of arginine required for optimal recovery of hTrx from a pH 5.0 
elution buffer was re-examined using 0.025 to 0.5 M arginine concentration range and 
their effect on hTrx recovery is shown in Figure 4.10, and compared as before to 1 M NaCl 
control. Similar to previous pH 7.0 elution buffer composition, hTrx was completely 
(100%) eluted from HEA HyperCel resin with 0.1 M arginine in 1.0 M NaCl acetate 
buffer. Lower and higher than 0.1 M arginine concentrations resulted in an “U-shaped” 
elution recovery trend consistent with the previous data with mixed-mode resins [34, 191]. 
Therefore, to maximize hTrx recovery, the optimal composition of the pH 5.0 elution 






Figure 4.10 Optimization of arginine HCl concentration in 1 M NaCl in pH 5 acetate 
buffer for recovery of hTrx in HEA HyperCel elution. The %hTrx recovery values were 
normalized with the highest recovery as 100%. Treatments not sharing the same letter 
are significantly different (α = 0.05). Error bars indicate standard deviation of triplicate 
measurements 
 
The adsorption studies so far were performed essentially under equilibrium 
conditions, and packed-bed chromatography was investigated next. The aim was to 
confirm the strong adsorption of hTrx during a much shorter contact time of 5 min 
compared to 30 min in batch experiments and verify the effectiveness of optimized elution 
buffer conditions. The chromatogram from packed-bed chromatography is shown in 
Figure 4.11, with fractions containing hTrx highlighted within the vertical orange lines. 
The recovery and purity of hTrx in these fractions were measured, along with the size and 






Figure 4.11 Chromatogram of hTrx purification by HEA HyperCel resin. Clarified 
lysate was loaded to PRC HEA column (1 mL) at 0.25 mL/min flowrate. Linear gradient 
of optimized elution buffer (0–1.0 M NaCl+ 0.1 M arginine HCl) at 0.5 mL/min was 
applied. hTrx eluted is shown as the shaded orange region between 43 - 65 mL 
 
The HEA elutions contained hTrx at 52.3% purity, and the recovery was 100%. 
The use of optimized elution buffer containing 0.1 M arginine HCl and 1.0 M NaCl at pH 
5 was effective in completely reversing the interactions and eluting hTrx bound to HEA 
HyperCel resin on a packed-bed column as well. The capture chromatography also 
reduced DNA content to 1.8x1011 µg, a 1-log reduction from the clarified lysate value. 
The turnover number, calculated from insulin reduction activity also increased to 7.1x10-

























































f-Insulin precipitation assay 
 
4.3.7 Analysis of Human Thioredoxin in Elution Fractions  
Another aspect to be analyzed to confirm multiple interaction mechanisms, is that 
the hTrx eluted by arginine and that by NaCl are the same isoform. Packed-bed 
chromatography was employed with first a gradient NaCl elution over 20 CV followed by 
10 CV elution with 0.2 M arginine HCl (NaCl-Arg), similarly another experiment with 
the elution order reversed, 10 CV elution with 0.2 M arginine HCl then a 20 CV gradient 
NaCl elution (Arg-NaCl). The elution fractions were individually analyzed for size 
distribution, shown in Figure 4.12. Peak “1” in chromatograms (Figure 4.12a and 4.12b) 
corresponds to HCP impurities, confirmed by SDS-PAGE (data not shown) and arginine 




volume. In both experiments, arginine and NaCl elution fractions contained 12 kDa hTrx 
eluting at 10.4 mL seen as peak “2”. There were no hTrx aggregates observed in the 
elutions, and both NaCl and arginine HCl were eluting hTrx in its monomer form. 
Insulin reduction activity is a characteristic of hTrx, and was used to confirm its 
identity (Figure 4.13a and 4.13b). In the case of NaCl-Arg, the two elutions also displayed 
insulin reduction activity with a turnover number of 7.7* 10-5 min-1 and 2.0* 10-5 min-1 
respectively. Similarly, in the case of Arg-NaCl, the turnover number was 3.9* 10-5 min-1 
and 1.3* 10-5 min-1 respectively. This established that both elution buffers removed hTrx 
of the same size from the column and the eluting fractions displayed hTrx activity.  
 
 
Figure 4.12 Analysis of size distribution using TSK gel 2000SWxL column for (a) 






Figure 4.13 Insulin-reduction activity of hTrx in (a) NaCl-Arg elution pools and (b) 
Arg-NaCl elution pools 
 
4.4 Discussion 
Thioredoxin is a potent therapeutic molecule with anticipated use for cystic 
fibrosis treatment. Manufacturing the necessary quantities (estimated ~2000 kg/year) of 
hTrx would not be efficient with the current downstream processes in terms of overall 
product yield and likely to be cost prohibitive. Improving the efficiency of the isolation 
process will translate to lower manufacturing cost and affordability of the therapeutic 
product.  
Current isolation processes for hTrx that employ anion exchange chromatography 
and hydrophobic interaction chromatography result in a significant (as much as 50%) loss 
in hTrx. Exploring single-mode resins shed light on the processing constraints of the 
current isolation methods. The main reasons for observed losses are related to inefficient 




of charge and hydrophobic amino acids on the surface of hTrx. For example, adsorption 
of hTrx to Capto Q resin required unrealistically low conductivity range (0 to < 2 mS), 
since the protein has a minimal net charge (-0.6) at the optimized lysis pH. Clarified cell 
lysate is at pH 5 and conductivity of 5 mS would have to be either significantly diluted or 
diafiltered to facilitate electrostatic interaction with Capto Q resin. Either procedure is not 
ideal from a processing stand point; dilution would increase the processing time for 
loading larger lysate volumes onto Capto Q packed-bed columns whereas the diafiltration 
is an additional unit operation that would increasing the cost and processing time. The 
critical process weakness is the low binding strength of hTrx on the strong anion exchange 
resin making Capto Q resin unsuitable for capture step. Similarly, the low hydrophobicity 
of hTrx (GRAVY = - 0.096), required > 2 M ammonium sulfate to bind the protein to the 
strongest hydrophobic resin (phenyl ligand). The main deficiency associated with 2 M 
ammonium sulfate was the upfront 30 % loss of hTrx due to salting-out.  
To overcome noted process constraints with Capto Q and hydrophobic interaction 
chromatography we resorted to mixed-mode adsorbents hoping to take advantages of dual 
adsorption mechanism to increase the protein binding capacity without the need for any 
substantial lysate conditioning (diafiltration or ammonium sulfate addition). Mixed-mode 
resin have not been extensively employed for direct capture from clarified lysates and 
thus, in the absence of data “brute-force” approach to select resins, i.e. high-throughput 
screening was undertaken. Mixed-mode resins were then explored for the benefits that 
could arise from multiple interaction chemistries. High-throughput screening was valuable 




conductivities. Of the resins screened several (Prometic ligands D1, D8, Capto adhere and 
HEA HyperCel) showed binding of hTrx under moderate salt-tolerant conditions (~5 mS). 
Amongst these resins, HEA HyperCel had consistently high relative binding ratio (k =1.2 
to 1.4) even in moderate conductivities. hTrx interaction with the resin across pH 6 to 8 at 
conductivities up to 10 mS, was indicative of a strong interaction. The elution of adsorbed 
hTrx with a high ionic strength (75 mS) buffer containing 1 M NaCl was insufficient to 
fully recover hTrx. This indicated that hTrx-HEA ligand interactions were not solely 
electrostatic. To address the low yield required further high-throughput screening focusing 
on elution buffers that could disrupt other intermolecular interactions. This led us to 
investigate buffer additives containing arginine HCl, guanidine HCl and lysine HCl, which 
are known to have ability to break hydrogen bonds, and electrostatic and hydrophobic 
interactions. Individual organic elution buffers (Figure 4.7a) in the absence of NaCl, were 
not significantly different in increasing hTrx recovery than 1 M NaCl alone. Upon 
examination of eluted proteins by SDS-PAGE (Figure 4.7b), the difference in the profile 
of HCPs, led to the hypothesis that the desorption mechanism of organic modifiers and 
NaCl was different. This behavior is characteristic of mixed-mode resins where a protein 
can interact with the ligand through multiple modes of interaction. Therefore, to maximize 
the recovery yield these different interaction mechanism need to be tackled simultaneously 
during elution [23]. Consistent with that, synergistic behavior was observed when elution 
buffers combined these organic modifiers at an optimized concentration of 0.1 M with 1 
M NaCl buffer, recovered 100% of hTrx from HEA HyperCel resin. Among the buffer 




Arginine HCl is known to preserve the structural stability of proteins. Protein denaturation 
in the presence of < 0.1 M guanidine HCl concentration was not expected hence was not 
the reason to exclude guanidine from further consideration, and actually guanidine could 
be an economically viable alternative to arginine. Comparing arginine and guanidine both 
of which share a guanidinium side chain, allows shedding light on the mechanism of hTrx. 
The guanidinium group present in both arginine and guanidine HCl, is electropositive and 
expected to reduce the electrostatic interaction. Arginine should have a stronger charge 
disruption effect because of its zwitter ionic property and steric hindrance from its alkyl 
group. Based on molecular modelling studies, both arginine and guanidine accumulate 
near the charged amino acids of proteins resulting in charge neutralization and desorption. 
They also promote hydrophobic interactions of the nearby amino acids with the resin. The 
enhancement of hydrophobic interactions with nearby amino acids would be more 
pronounced in the presence of guanidine HCl than arginine due to the steric hindrance 
effect of bulkier arginine molecule [192]. Hydrophobic interactions could also explain the 
“U-shaped” elution observed with > 0.1 M elution buffer modifiers when added to 1 M 
NaCl containing elution buffer (Figure 4.10). 
Molecular simulation helped to better understand experimental observation. The 
primary mode of interaction at pH 5 is electrostatic and van der Waals (hydrogen bonding). 
Despite being close to the pI of the protein, the acidic residues (aspartic and glutamic 
acids) retain charge at pH 5 and interact with the HEA ligand. Simulation data confirm 




bonding with the aspartic and glutamic amino acids and completely reverse the 
interactions with the ligand.  
Capture chromatography performed on 1 mL packed-bed column was consistent 
with the trend observed from high-throughput and equilibrium adsorption studies. The 
optimized elution buffer successfully recovered 100% of hTrx with a purity of 52.3%. The 
purity with packed-bed chromatography was lower than 67% achieved in batch 
chromatography experiments. The discrepancy can be attributed to a couple of reasons. 
First, due to inconsistencies in cell disruption by sonication, the starting purity of the lysate 
used in packed-bed chromatography was 20.5% (% HCP or TSP) compared to 30% used 
in the batch chromatography experiments. Second, there was a larger volume of clarified 
lysate loaded per ml of HEA HyperCel resin, which would increase the amount of 
impurities that bind and then co-elute with hTrx. There was no breakthrough of hTrx 
observed in the flow through, so the loading was within the binding capacity of the 
chromatography resin and there was no hTrx lost or unaccounted for in the mass balance. 
Clearly, there is room for further optimization of the HEA capture chromatography as 
further process development to reach the therapeutic standards of hTrx. 
4.5 Conclusions 
This study explored the pitfalls of using single-mode chromatography resins as it 
applies to hTrx isolation and the resulting product loss. Mixed-mode chromatography 
resins were explored to take advantage of better selectivity and direct loading in moderate 




Custom and commercial mixed mode resins displaying direct binding of hTrx from 
clarified lysate were narrowed down using high-throughput screening based on their 
selective binding of hTrx and HCPs. HEA HyperCel provided the maximum purity of 
67% with a 45% recovery of hTrx by batch chromatography and was chosen as the capture 
chromatography because 1) allowed for direct binding of cell lysate without conditioning, 
2) higher purity was obtained in the elutions 3) the interaction with HEA ligand was 
stronger and required higher NaCl concentrations to elute compared to other resins. Since 
recovery of high value therapeutic product is paramount for process efficiency, especially 
early in the isolation process, elution was optimized to improve recovery. 
The optimized elution buffer of 50 mM sodium acetate, 1.0 M NaCl, 0.1 M 
arginine HCl, 5 mM DTT, pH 5 resulted in complete hTrx elution, while the individual 
buffer components could not elute all of the bound hTrx. Consequently, a true mixed-
mode interaction exists where one isoform of hTrx interacts through multiple mechanisms 
with the HEA HyperCel resin. The nature of these interactions were determined by 
molecular modelling and discovered as electrostatic and van der Waals interactions 
(hydrogen bonding). More importantly, optimized concentration of buffer components 
was crucial in elution, since hTrx binding with the resin was promoted at > 0.1 M 
concentration of arginine HCl in the elution buffer. Packed-bed chromatography under 
direct loading and optimized elution conditions resulted in 52.3% purity and 100% hTrx 
recovery. Through understanding the mechanism of protein-ligand interaction, the 
recovery was significantly increased, while maintaining > 50% elution purity. With 100% 




elution strategy to maximize the hTrx purity obtained from HEA HyperCel 
chromatography. The highly efficient capture chromatography alleviates the recovery 
burden on subsequent processing steps and sets precedent for a thoroughly optimized 
process. 
The hTrx obtained from HEA HyperCel was confirmed to be biologically active 
with a turn over number of 7.1x10-5 min-1 and oxidized aggregates were not present in the 
elutions. Clearly, there is need for an additional chromatography or purification unit 
operation to reach the therapeutic standards of 99.9% purity and 125 ng DNA/ g of hTrx.  
In summary, this study establishes that HEA HyperCel mixed-mode resins can be 
applied to crude lysate for direct capture of non-mAb therapeutic protein. Molecular 
modelling was applied to reveal the specific sites of protein-ligand interaction and its 
behavior under experimental conditions. The information gained bolstered the 
understanding of the process and reinforced the experimental findings. Scaled-down high-
throughput screening was applied for binding and elution optimization, which successfully 
translated to packed-bed chromatography. Combining the knowledge from literature, 
computation modelling and high throughput screening, an active hTrx at 100% recovery 






Downstream processing contributes to 50-80% of the cost of therapeutic 
manufacturing. Mixed-mode resins are an emerging class of chromatographic stationary 
phase media, known for their high selectivity. Their application in purification of 
therapeutic proteins is still nascent. In this study, mixed-mode resins were applied to the 
downstream processing of two therapeutic proteins to gain insights into the challenges and 
benefits of mixed-mode resins. The two proteins studied suffered from multi-
chromatography downstream process, due to processing difficulties arising from low 
expression titer, impurity profile, lack of charge or hydrophobic properties, etc. and stand 
to benefit from integrating mixed-mode resins in their downstream process. The following 
results and conclusions were made from each study. 
5.1 Isolation of Osteopontin from C. reinhardtii Lysate Using CHT Resin 
The ability of microalgae, C. reinhardtii to express OPN in its phosphorylated 
form was confirmed, although the starting purity was a low 0.1-0.2%. Additionally, 
multiple isoforms of pI ranging from 3.5 to 4.5 and fragments of 35 kDa were detected. 
Knowledge-based process development led to testing mixed-mode CHT resin to capture 
phosphorylated OPN. Direct capture of OPN from algal lysate, at pH 6.8 resulted in strong 
interactions of 70% of the OPN with mixed-mode CHT resin, requiring 1500 mM NaP 
followed by 100 mM NaOH to recover the bound OPN. The protein-ligand interaction 
was challenged by binding in the presence of 250 mM NaCl, which interestingly promoted 




negatively charged groups. Conversely, binding in 250 mM NaCl discouraged interaction 
of non-phosphorylated E. coli OPN, as 83% remained unbound. This confirmed that 
OPN’s interaction with CHT resin was through multiple chemistries, the non-
phosphorylated E. coli OPN interacted primarily through electrostatic interactions, while 
phosphorylated OPN necessitated NaP buffer to competitively elute the Ca2+–PO3
2− 
coordinate binding. However, CHT as the capture chromatography was ineffective in 
resolving phosphorylated algal impurities, such as Rubisco, from OPN. Therefore, 
alternate capture chromatography using anion exchanger, Capto Q resin was used, to 
separate Rubisco and before CHT chromatography. Such a two-step process resulted in 
33% OPN recovery and 75% purity, which was a 375-fold increase from the lysate purity. 
In this case, a three-chromatography process would be necessary to obtain OPN in 
therapeutic specification. The low starting purity, combined with multiple isoforms were 
detrimental to protein recovery and quantification.  
5.2 Application of HEA HyperCel Mixed-Mode Resin for the Capture of OPN 
from E. coli Lysate 
Mixed-mode resins for the capture of osteopontin in the absence of 
phosphorylation were explored. Scaled-down, high-throughput screening studies 
predicted the binding chemistries offered. HEA HyperCel resin bound OPN at 150 mM 
NaCl and again at 3 M NaCl concentration, indicating a shift in retention modes from 
primarily electrostatic to hydrophobic binding based on salt conditions. PPA HyperCel, 
consistently bound OPN across the tested binding pH and conductivity, but the recovery 




pH and conductivity, offering no benefit in purity or recovery compared to single-mode 
anion exchange chromatography, Capto Q resin. Of the resins studied, binding to mixed-
mode HEA HyperCel resin offered highest purification fold of 14, and recovery of 76%. 
Mixed-mode resins were a viable capture chromatography for OPN from E. coli lysate, 
increasing the purity of the lysate from 1.9% to 29%. After buffer exchange to reduce the 
conductivity, anion exchange chromatography was employed to increase the purity of the 
HEA elution to 95%. The typical 3 or more chromatography process used for purification 
of OPN was reduced to a 2-chromatography downstream process by using mixed-mode 
resins. 
5.3 Mixed-Mode Resin Screening for the Capture and Recovery of Human 
Thioredoxin from E. coli Lysate 
The downstream processing of human thioredoxin suffers from the lack of charge 
and hydrophobic properties, despite high expression titers. Direct comparisons between 
the limitations of single-mode resins were made with the possibilities offered by mixed-
mode resins. Comparison of resin selectivity and salt-tolerant interactions were made 
possible by high-throughput screening. Mixed-mode HEA HyperCel resin had a 
consistently high relative binding ratio of 1.4 across pH and conductivities up to 10 mS. 
It offered direct capture of hTrx from clarified lysate and resulted in a 66.6% purity at 40 
% recovery with 1 M NaCl elution. Molecular modeling revealed combined retention 
mode, electrostatic and hydrogen bonding between protein-ligand that required individual 
buffer components to address. The optimized concentration of organic buffer modifier, 




from the capture chromatography. Packed-bed chromatography under the optimized 
binding and elution conditions was used to confirm that biologically active hTrx at 52.3% 
purity and in monomer form was obtained from HEA HyperCel chromatography. 
5.4 Recommendations for Further Process Development of Therapeutic Proteins 
The following recommendations are to continue the study described in Chapter 
II- 
i. Increasing OPN expression titers in C. reinhardtii is mandatory for further 
process development and scaling the suggested process to packed-bed 
chromatography 
ii. Investigate the selectivity of CHT resin towards degree of phosphorylation in the 
phosphorylated OPN isoforms 
iii. Explore other mixed-mode resins alternates to capture and resolve Rubisco from 
OPN. Followed by a comparison with single-mode anion exchange 
chromatography.  
The following recommendations are to continue the study described in Chapter III- 
i. Improve OPN recovery in the dialysis operation 
ii. Determine the binding capacity to optimize OPN loading on packed-bed column.  
iii. Characterize the OPN elutions for protein activity, isoforms and contaminant such 
as DNA, endotoxins 





i. Explore pretreatment methods such as flocculation with charged polymers prior to 
capture chromatography, to reduce DNA, charged HCP impurities and improve 
hTrx binding capacity on HEA HyperCel resin.  
ii. Optimize protein loading and wash to maximize elution purity achieved from HEA 
HyperCel chromatography 
iii. Explore mixed-mode resins options for the next chromatography to achieve 
therapeutic purity and assemble the downstream process 
iv. Perform molecular modelling at different organic modifier concentrations to 
understand the mechanism behind “U-shaped” elution behavior of hTrx from HEA 
HyperCel chromatography  
v. Analyze the economic impact of mixed-mode resin on downstream processing cost 
5.5 Mixed-Mode Resins Conclusion 
The above cases are in no means exhaustive analysis on the capabilities of mixed-
mode resins, but a representation to understand their performance under challenging 
processing situations of low starting purity, contrasting expression titers (0.1-0.2% vs 
30%), varying impurity protein profile and specific challenges related to the expression 
hosts. The following conclusions can be drawn from the three studies regarding mixed-
mode resins.  
1. They were capable of handling complex lysates, from C. reinhardtii and E. coli 
cells and capture the therapeutic protein from it. Mixed-mode CHT resin was 
insensitive to low expression titers and starting purity, especially considering the 




HyperCel resin also fared well at both 1.9% starting purity of OPN and high ~30% 
starting purity of human thioredoxin, enduring the large (> 30 mg/ml) protein load 
and still providing selectivity. Mixed-mode resins were versatile and could be used 
for direct capture from complex lysates as well as intermediate chromatography.  
2. Mixed-mode resins offer wider range of compatible binding pH and salt 
concentration. Electrostatic interactions at low to moderate conductivities were 
crucial for direct lysate binding. Such functionalities overcome the need for 
conditioning operations like diafiltration, saving processing cost and time.  
3. Mixed-mode resins offer multiple interactions, these can be individual 
interactions, based on binding condition or combined interactions, based on 
property of the protein. For example, HEA HyperCel resin, displayed individual 
electrostatic interaction with OPN at low salt concentration and shifted to 
hydrophobic interaction when bound at 3 M NaCl. In the case of hTrx, electrostatic 
and van der Waals interaction with the HEA ligand were simultaneous and resulted 
in strong interaction strength.  
4. The protein-ligand interactions are driven by the properties of the protein. For 
example, the same HEA HyperCel resin interacted primarily by electrostatic 
interaction with OPN but through a combination of electrostatic and van der Waals 
interaction with hTrx. HEA HyperCel offers electrostatic, hydrogen bonding and 
hydrophobic interaction chemistry, but it is the property of the protein that dictates 




conditions cannot be applied, but proven strategies to counteract the interaction 
mechanisms can be suggested. 
Some of the challenges with mixed-mode resins were revealed during the course 
of this study are summarized below- 
1. The complexities arising from combining multiple interactions make mixed-mode 
resins notorious for low product recovery. One has to recognize that multiple 
interactions while offering opportunity to achieve new enhanced separation 
selectivity, might not always be beneficial. For example, complete hTrx recovery 
demanded extensive buffer optimization studies and modelling protein-ligand 
interactions to develop a successful elution strategy. Another case that required 
intervention was phosphorylated OPN interacting with CHT resin. Apart from the 
simultaneous electrostatic and coordination bonding, there was undesirable 
electrostatic repulsion between phosphoryl groups in the protein and phosphate 
groups in the resin, which required suppression of electrostatic repulsions with 250 
mM NaCl for complete binding 
2. Thorough understanding of protein-ligand interaction mechanism and 
optimization of binding and elution conditions, is key to overcoming low protein 
recovery from some mixed-mode resins and achieving their potential. Knowledge-
based approach presumes understanding of the process related impurities and 
protein-ligand interaction mechanism. In the cases of poorly understood systems, 
the experimental load could be immense and eventually result in an inefficient 




screening and molecular modelling were successfully employed to 
comprehensively understand the possible interactions with the resin and reduce the 
experimental trial-and-error required. 
3. The presence of protein isoforms and impurities containing binding motifs similar 
to the target protein could defy the use of mixed-mode interactions. This challenge 
was encountered with CHT resin, where the selectivity of the mixed-mode resin 
was reduced in the presence of Rubisco, a host cell impurity protein that has similar 
properties to OPN. The poorly understood OPN structure limits our ability to 
further exploit the complex CHT chemistry and determine the capacity of CHT to 
resolve isoforms based on phosphorylation. 
Recommendation for future work include- 
1. Perform techno-economic analysis on using HEA HyperCel mixed-mode resins as 
capture chromatography 
2. Future process development starting with modelling the protein-ligand interaction, 
followed by experimental optimization would be ideal for downstream process 
development efficiency 
3. Expand the library of information on therapeutic proteins and their interaction with 
the most promising mixed-mode resins through molecular modelling 
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Figure A1 Anti-FLAG western blot of (a) E. coli OPN binding and elution profile 
without 250 mM NaCl (b) C. reinhardtii OPN binding and elution profile with 250 mM 
NaCl (c) E. coli OPN binding and elution profile with 250 mM NaCl from ceramic 
hydroxyapatite (CHT) resin. All samples diluted to <1 mg/mL total soluble protein 
(TSP). Lane 1. Molecular weight (MW) marker, lane 2. Clarified lysate, lane 3. 
Supernatant, lane 4. Washes 3 column volumes (CV), lane 5. Elution with 100 mM NaP, 
lane 6. Elution with 250 mM NaP, lane 7. Elution with 500 mM NaP, lane 8. Elution 
with 1000 mM NaP, lane 9. Elution with 1500 mM NaP, lane 10. Elution with 100 mM 





Figure A2 Anti-FLAG western blot of (a) C. reinhardtii OPN (b) E. coli OPN binding 
and elution profile from Ga-IMAC resin. All samples diluted to <1 mg/mL TSP. Lane 1. 
MW marker, lane 2. Clarified lysate, lane 3. Supernatant, lane 4. Washes (3 CV), lane 5. 
Elution with 100 mM NaP, lane 6. Elution with 250 mM NaP, lane 7. Elution with 500 
mM NaP, lane 8. Elution with 1000 mM NaP, lane 9. Elution with 1500 mM NaP. All 
elutions were performed with 5 CV of the respective buffer  
 
Figure A3 (a) Anti-Rubisco large subunit (b) Anti-Rubisco small subunit western blots 
of C. reinhardtii OPN samples. All samples diluted to <1 mg/mL TSP. Lane 1. MW 
marker, lane 2. C. reinhardtii clarified lysate, lane 3. Elution with 100 mM NaOH from 
ceramic hydroxyapatite (CHT) resin, lane 4. Elution with 200 mM NaCl from Capto Q 







Figure A4 Interaction fraction (or contact period) over the course of the trajectory 
(240ns) for hTrx amino acids with HEA ligand are shown in bar chart under the 
following simulation conditions (a) 0.05 M NaCl, (b) 1 M NaCl, (c) 0.2 M arginine and 
(d) 1 M NaCl + 0.2 M arginine. The values over one are possible as some protein residue 
may make multiple contacts of same subtype with the ligand. 
